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Abstract——Systems medicine has a mechanism-based
ratherthanasymptom-ororgan-basedapproachtodisease
and identifies therapeutic targets in a nonhypothesis-
drivenmanner. In thiswork,we apply this to transcription
factor nuclear factor (erythroid-derived 2)–like 2 (NRF2)
by cross-validating its position in a protein–protein
interaction network (the NRF2 interactome) functionally
linked to cytoprotection in low-grade stress, chronic
inflammation, metabolic alterations, and reactive oxygen
species formation. Multiscale network analysis of these
molecularprofiles suggestsalterationsofNRF2expression
and activity as a common mechanism in a subnetwork
of diseases (the NRF2 diseasome). This network joins
apparently heterogeneous phenotypes such as autoimmune,
respiratory, digestive, cardiovascular, metabolic,
and neurodegenerative diseases, along with cancer.
Importantly, this approach matches and confirms
in silico several applications for NRF2-modulating
drugs validated in vivo at different phases of clinical
development. Pharmacologically, their profile is as
diverse as electrophilic dimethyl fumarate, synthetic
triterpenoids like bardoxolonemethyl and sulforaphane,
protein–protein or DNA–protein interaction inhibitors,
and even registered drugs such as metformin and
statins, which activate NRF2 and may be repurposed
for indications within the NRF2 cluster of disease
phenotypes. Thus, NRF2 represents one of the first
targets fully embraced by classic and systems medicine
approaches to facilitate both drug development and
drug repurposing by focusing on a set of disease
phenotypes that appear to be mechanistically linked.
The resulting NRF2 drugome may therefore rapidly
advance several surprising clinical options for this
subset of chronic diseases.
I. Introduction
Life span has almost doubled in the last century, and
aging-specific diseases are now becoming prevalent. How-
ever, the pathologic mechanisms underlying most of them
are poorly understood and treated rather by correcting
symptoms or risk factors. Moreover, contrary to a hitherto
linear approach that considered one disease, one medicine,
chronic diseases demonstrate a high degree of connected-
ness and a need formore precise,mechanism-based disease
definitions rather than the current organ- and symptom-
based. After the human genome sequencing and the devel-
opment of molecular networks, a new concept of disease is
thus emerging, in which diseases are diagnosed not only by
clinical symptoms, but mainly by the underlying molecular
signatures (Goh et al., 2007). The fact that different
pathophenotypes have a shared molecular mechanism
provides also a rationale toward a new concept of therapy
summarized as “several diseases, one medicine” and drug
repurposing. Network medicine, i.e., the application of
network concepts to the analysis of dynamic connections
among diseases and drugs, provides a new opportunity to
develop this new approach. Chronic diseases in the elderly
are most likely characterized by the loss of homeostasis
during aging or as a result of environmental factors, all of
them leading to low-grade stress by pathologic formation of
reactive oxygen species (ROS), chronic inflammation, and
metabolic unbalance. Based on a network medicine ap-
proach, in this review we will present extensive evidence
indicating that thenuclear factor (erythroid-derived 2)–like
ABBREVIATIONS: AD, Alzheimer disease; ALS, amyotrophic lateral sclerosis; AMPK, AMP-activated protein kinase; ARE, antioxidant response
element; b-TrCP, b-transducin repeat containing E3 ubiquitin protein ligase; bZip, basic region-leucine zipper; CDDO, 2-cyano-3,12-dioxo-oleana-1,9(11)-
dien-28-oate; CDDO-Me, CDDO-methyl ester; COPD, chronic obstructive pulmonary disease; CUL3, Cullin 3; DC, dendritic cell; DMF, dimethyl
fumarate; EAE, experimental autoimmune encephalomyelitis; ECH, erythroid cell–derived protein with Cap’n’collar homology; GCLC, g-glutamyl
cysteine ligase catalytic subunit; GCLM, g-glutamyl cysteine ligase modulator subunit; GI, gastrointestinal tract; GSH, glutathione; GSK-3, glycogen
synthase kinase 3; HFD, high-fat diet; HNSCC, head and neck squamous cell carcinoma; HO-1, heme oxygenase-1; IBD, inflammatory bowel disease;
IkB, k-B inhibitor; IKK, IkB kinase; IL, interleukin; KEAP1, kelch-like ECH-associated protein 1; LDL, low-density lipoprotein; LPS, lipopolysaccharide;
MAF, musculoaponeurotic fibrosarcoma protein; MMF, monomethyl fumarate; MS, multiple sclerosis; NASH, nonalcoholic steatohepatitis; NF-kB, p65
subunit of nuclear factor k-light-chain enhancer of activated B cells; NQO1, NADPH:quinone oxidoreductase; NRF2, nuclear factor (erythroid-derived 2)–
like 2; PD, Parkinson disease; PI3K, phosphatidylinositol 3-kinase; PPI, protein–protein interaction; PTEN, phosphatase and tensin homolog; RA,
rheumatoid arthritis; RBX1, RING-box protein 1; RNS, reactive nitrogen species; ROS, reactive oxygen species; SFN, sulforaphane; SLE, systemic lupus
erythematous; SNP, single-nucleotide polymorphism; SQSTM1, sequestosome 1; STAT, signal transducer and activator of transcription; T2DM, type
2 diabetes mellitus; TGF, transforming growth factor; Th, T helper; TNF, tumor necrosis factor; Treg, T regulatory.
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2 (NRF2), as the master regulator of multiple cytoprotec-
tive responsesandakeymolecularnodewithinaparticular
cluster of diseases, provides a new strategy for drug
development and repurposing.
II. From Nuclear Factor (Erythroid-Derived 2)–
Like 2 Interactome to Nuclear Factor (Erythroid-
Derived 2)–Like 2 Diseasome
A. Nuclear Factor (Erythroid-Derived 2)–Like 2 as a
Master Regulator of Cellular Homeostasis
NRF2 is a basic region-leucine zipper (bZip) tran-
scription factor (Fig. 1) that forms heterodimers with
small musculoaponeurotic fibrosarcoma protein (MAF)
K, G, and F in the nucleus. The heterodimer recognizes
an enhancer sequence termed antioxidant response
element (ARE) that is present in the regulatory regions
of over 250 genes (ARE genes) (Ma, 2013; Hayes and
Dinkova-Kostova, 2014). These ARE genes encode a
network of cooperating enzymes involved in phase I, II,
and III biotransformation reactions and antioxidant
mechanisms that generate NADPH, glutathione
(GSH), and thioredoxin reactions; lipid and iron ca-
tabolism; and interaction with other transcription
factors, etc. (Hayes and Dinkova-Kostova, 2014). Re-
cently, NRF2 was also found to regulate the expres-
sion of several proteasome subunits and autophagy
genes, providing additional interest for its control of
proteostasis (Pajares et al., 2015, 2016, 2017; de la
Vega et al., 2016).
The great significance of NRF2 from a clinical perspec-
tive is that it might be targeted pharmacologically with
patient benefit. The main mechanism regulating the
transcriptional activity of NRF2 is the control of protein
stabilization by the E3 ligase adapter Kelch-like erythroid
cell–derived protein with Cap’n’collar homology (ECH)-
associated protein 1 (KEAP1) (Fig. 2). KEAP1 is a
homodimeric protein that bridges NRF2 with the E3
ligase complex formed by Cullin 3 and RING-box protein
1 (CUL3/RBX1). Under homeostatic conditions, the
N-terminal domain of the KEAP1 homodimer binds
one molecule of NRF2 at two amino acid sequences
with low (aspartate, leucine, and glycine; DLG) and high
(glutamate, threonine, glycine, and glutamate; ETGE)
affinity, and hence presents NRF2 to ubiquitination by
CUL3/RBX1 (Tong et al., 2007) and subsequent degrada-
tion by the proteasome.KEAP1 is a redox and electrophile
sensor that uponmodification of critical cysteines loses its
ability to repress NRF2 (Fig. 2; Biomarkers as Nuclear
Factor (Erythroid-Derived 2)–Like 2 Signature and for
Monitoring Target Engagement). An alternative mecha-
nism of regulation of NRF2 stability is the phosphorylation
mediated by glycogen synthase kinase 3 (GSK-3) (Fig. 2).
This kinase phosphorylates a domain of NRF2 (aspartate,
serine, glycine, isoleucine, serine;DSGIS) andhence creates
a recognition motif for the E3 ligase adapter b-transducin
Fig. 1. NRF2 as a master regulator of cytoprotective responses. (A) NRF2 heterodimerizes with the members of MAF family through their bZip
domain. The heterodimer binds to an enhancer sequence termed ARE that is present in the regulatory regions of over 250 genes (ARE genes). (B) These
genes participate in the control of redox metabolism, inflammation, and proteostasis balance, as indicated. The existence of susceptibility SNPs in
NFE2L2, elevated levels of its target genes in brain necropsies, and positive data from preclinical studies suggests that the imbalance in proteostasis,
redox, and inflammatory control may be counterbalanced by NRF2 activation. ACl, ATP citrate lyase; ACC1, acetyl-coenzyme A carboxylase 1;
CALCOCO2, calcium binding and coiled-coil domain 2; cGS, c-glutamate cysteine synthetase; FAS, fatty acid synthase; G6PDH, glucose-6-phosphate
dehydrogenase; Gpx, glutathione peroxidase; Gpx8, gluthation peroxidase 8; GR, glutathione reductase; HMOX1, heme oxygenase-1; IDH1, isocitrate
dehydrogenase 1; ME, malic enzyme; MTHFD2, methylenetetrahydrofolate dehydrogenase 2; PGD, phosphogluconate dehydrogenase; PPAT,
phosphoribosyl pyrophosphate amidotransferase; PSMB7, proteasome subunit b type-7; SCD1, stearoyl-CoA desaturase; TrxR, thioredoxin reductase;
ULK1, unc-51 like autophagy activating kinase 1.
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repeat containing E3 ubiquitin protein ligase (b-TrCP) that
presents NRF2 to a CUL1/RBX1 complex, leading to an
alternative pathway for ubiquitin-dependent proteasome
degradation of NRF2. Therefore, KEAP1 and GSK-3/
b-TrCP tightly control NRF2 protein levels in the context
of redox homeostasis and cell signaling, respectively
(Cuadrado, 2015). Other mechanisms of NRF2 regulation
at protein, mRNA, or gene level have been reported
(Hayes and Dinkova-Kostova, 2014), but at least these
two are amenable to pharmacological regulation.
B. Positioning Nuclear Factor (Erythroid-Derived 2)–
Like 2 and Its Regulatory Pathway in the Human
Interactome and Diseasome
The gene encoding NRF2, termed NFE2L2, is highly
polymorphic and presents a mutagenic frequency of 1 per
every 72 bp. An excellent review on this topic reported in
2015 up to 18 single-nucleotide polymorphisms (SNPs),
most of them in the 59 regulatory region and in intron
1 (Cho et al., 2015). Several of these SNPs might
constitute functional haplotypes that are associated with
risk at onset or progressionof chronic diseases. Variations
in functional haplotypes may have a subtle impact on a
proportion of individualswho exhibit clinical symptoms of
specific diseases, yet they may have a profound effect at
the population level and may define specific strategies to
target this gene in precision medicine.
Recent advances in network medicine have provided
quantitative tools to characterize how the interplay
between genes and their interactions (interactome) is
related to pathology (Barabasi et al., 2011; Vidal et al.,
2011; Guney et al., 2016), how dysregulated molecular
networks are common to various diseases (Menche et al.,
2015), and how diseases manifest in particular tissues
(Kitsak et al., 2016). To understand the relevance of
NRF2 in pathology from the systems medicine perspec-
tive, first we have generated the human interactome
map. We have integrated and curated information on
physical interactions among proteins involved in the
NRF2-regulating pathway (Hayes andDinkova-Kostova,
2014; Cuadrado, 2015). The interaction data have been
taken from the recently published human interactome
that compiles data across several protein–protein in-
teraction (PPI) resources (Turei et al., 2013; Menche
et al., 2015). However, the currently available informa-
tion for development of the NRF2 interactome is limited
by the fact that, because NRF2 is a very short half-life
protein, some meaningful interactions may be unde-
tected. Nevertheless, some well-known proteins that
physically interact with NRF2 are found in the inter-
actome, including KEAP1, b-TrCP, and MAFs. Another
group of NRF2-interacting proteins corresponds to nu-
clear proteins with functions in regulation of gene
expression. These include proteins related with bZip
transcription factors, nuclear receptors or coactivators,
or proteins involved in histone acetylation. Therefore,
the NRF2 interactome evidences additional mechanisms
of gene regulation beyond those directly connected to this
Fig. 2. Regulation of NRF2 stability by KEAP1 and b-TrCP and its pharmacological targeting. (A) According to the dual regulation model (Rada et al.,
2011), two domains of NRF2, termed Neh2 and Neh6, participate in NRF2 degradation in response to redox and electrophile changes (KEAP1) and to
signaling kinases (b-TrCP), respectively. The Neh2 domain binds the E3 ligase adapter KEAP1 that presents NRF2 for ubiquitination to a CUL3/RBX1
complex. The Neh6 domain requires previous phosphorylation by GSK-3 to bind the E3 ligase adapter b-TrCP and subsequent ubiquitination by a
CUL1/RBX1 complex (see text for details). (B) Detail of the binding between NRF2 and KEAP1 and current strategies to target this interaction. The
KEAP1 homodimer binds NRF2 at two motifs of the Neh2 domain: the low-affinity (29-DLG-31) and the high-affinity (79-ETGE-82) binding sites.
Current strategies to disrupt this interaction include the following: electrophiles that alter sulfhydryl groups of cysteines C151, 273, and 288; PPI
inhibitors that alter the docking of NRF2 to the DC domain of KEAP1. (C) Hypothetical binding of NRF2 and b-TrCP and suggested strategies to target
this interaction. The b-TrCP homodimer binds to the Nhe6 domain at the phospho-motif 334-DSGIS-338 when it is phosphorylated by GSK-3 (Rada
et al., 2011, 2012) and at the phospho-motif 373-DSAPGS-378 independently of GSK-3 (Chowdhry et al., 2013). In this figure we postulate that, by
analogy with KEAP1, one b-TrCP homodimer interacts with one molecule of NRF2 at the two phospho-motifs, but experimental evidence is still
lacking. Two possible strategies to disrupt this interaction include the use of GSK-3 inhibitors and PPI inhibitors.
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transcription factor. NRF2 is phosphorylated at several
residues, and therefore it is expected to interact with
several kinases that include GSK-3 and several protein
kinase C isoforms. These kinases are downstream of
somemembrane receptors and adapter/scaffold proteins.
In addition to this physical interaction, we have identi-
fied several biologic functions that are enriched in the
NRF2 neighborhood, includingmetabolic processes, such
as biosynthesis of pentose, tetrapyrrole, heme, glucose
6-phospate, cysteine, GSH, glyceraldehyde-3-phosphate,
and NADPH. Most of these regulatory proteins do not
interact directly with each other but are connected
through proteins acting as mediators (Fig. 3; a more
detailed description of specific interacting molecules can
be found at http://sbi.imim.es/data/nrf2/).
Perturbations of the NRF2 interactome have been
reported in several diseases. We have developed a dis-
easomemapby curating a list of 37NRF2-related diseases
based on DisGeNET (Pinero et al., 2017) and GeneCards
(Stelzer et al., 2016) databases, as well as knowledge from
some studies in animal models. We have also retrieved
disease–gene associations for these pathologies using
DisGeNET, OMIM, and GWAS databases (Menche
et al., 2015) (Table 1). The interactome-based proximity
(Guney and Oliva, 2014) of NRF2 to known disease
genes for each of the NRF2-related disease phenotypes
is shown in Fig. 4. NRF2 is significantly closer to the
known disease genes of the digestive system and cancers,
such as prostate, liver, and lung neoplasms, compared
with randomly selected proteins, highlighting the key
functional role of NRF2 in these pathologies. Moreover,
NRF2was found to be proximal to various proteins related
to metabolic and cardiovascular diseases, such as di-
abetes, hyperglycemia, ischemia, middle cerebral artery
infarction, and atherosclerosis. Protein interactions of
NRF2 also connect it to genes associated to respiratory
disorders such as asthma, pulmonary fibrosis, and pul-
monary emphysema, as well as to neurodegenerative
conditions such as Alzheimer disease (AD), Parkinson
disease (PD), and amyotrophic lateral sclerosis (ALS).
The interactome-based proximity therefore offers a
perspective on how NRF2 can be linked to various
pathologic conditions. The relationships among diseases
have been previously summarized as a network, termed
diseasome, that is connecting them based on genetic (Goh
et al., 2007) and clinical (Hidalgo et al., 2009; Zhou et al.,
2014) commonalities. In Fig. 5, we have defined a network
of diseases, the NRF2 diseasome, based on shared genes,
symptom similarity, and comorbidities. NRF2 appears to
connect diseases governed substantially by inflammatory
processes, such as acute kidney injury, liver cirrhosis, and
atherosclerosis. Furthermore, neurodegenerative dis-
eases such as AD, PD, Huntington’s disease, and ALS
constitute a cluster consistent with recent studies impli-
cating also NRF2 in neuroinflammatory processes (Rojo
et al., 2010; Lastres-Becker et al., 2012, 2014; Jung et al.,
2017; Wang et al., 2017b). The regulation of NRF2 by
kinase-signaling cascades (Jung et al., 2017) could explain
the well-connected cluster of cancers, particularly sup-
porting the involvement of NRF2 in pathologic ROS
Fig. 3. Locating the NRF2 regulatory pathway in the human interactome. NRF2 plays a key role in pathologic ROS formation as well as inflammatory
and metabolic responses by coordinating the activity of various proteins. These interactions constitute a molecular interaction network, the NRF2
interactome. The known physical interactions between proteins involved in the NRF2 regulatory pathway (i.e., regulator proteins, brown circles) and
the proteins through which they are connected (i.e., mediator proteins, green circles) are shown with a gray link. The regulator proteins that involve
more than one mediator protein to connect to NRF2 are shown with a blue link. The regulator proteins are curated from literature, and their
interactions are retrieved from various resources, including IntAct, MINT, BioGRID, HPRD, KEGG, and PhosphoSite. The list of all the proteins that
interact with NRF2 in the human interactome is available online at http://sbi.imim.es/data/nrf2/.
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formation underlining colon (Gonzalez-Donquiles et al.,
2017) and breast (Lu et al., 2017) tumors.
III. Target Validation of Nuclear Factor
(Erythroid-Derived 2)–Like 2 in Human
Disease States
A. Key Role of Nuclear Factor (Erythroid-Derived 2)–
Like 2 in Resolution of Inflammation
Persistent inflammation is a hallmark of all patho-
phenotypes found in the NRF2 diseasome. This is
most likely because inflammation is associated with
increased local and systemic pathologic formation of
reactive oxygen species (ROS). In fact, ROS and reactive
nitrogen species (RNS) stimulate and aggravate in-
flammatory responses that are mechanistically related
to the activation of transcription factor, p65 subunit of
nuclear factor k-light-chain enhancer of activated
B cells (NF-kB) (Wenzel et al., 2017). Very simplified,
in resting immune cells, NF-kB is retained in the cytosol
through interaction with the nuclear k-B inhibitor
(IkBa). Pathogen-associated molecular pattern mole-
cules derived from microorganisms as well as damage-
associated molecular pattern molecules released in
TABLE 1
Cluster of diseases with evidence of NRF2 association
Disease phenotypes with evidence of genetic association with NRF2 were selected from the DisGeNet database. DisGeNet integrates disease–
gene association information from various resources, such as UniProt, ClinVar, GWAS Catalog, and Comparative Toxicogenomics Database and
scores disease–gene associations according to the number of resources and publications supporting these associations. The curation of the list was
based on the following criteria: 1) only pathophenotypes with more than one citation in Pubmed were selected; 2) the score of reliability was set to
a threshold of 0.001; and 3) disease entries with very similar names or overlapping terms were simplified to one single entry.
Pathophenotype Reliability Score Pathophenotype Reliability Score
Diabetic nephropathy 0.2016 Diabetic cardiomyopathy 0.0803
Liver cirrhosis 0.2005 Middle cerebral artery infraction 0.0800
Nonalcoholic steatohepatitis 0.2005 Breast neoplasms 0.0087
Acute kidney injury 0.2000 Vitiligo 0.0076
Pulmonary fibrosis 0.2000 Atherosclerosis 0.0067
Nonsmall cell lung carcinoma 0.1252 Asthma 0.0043
Squamous cell carcinoma 0.1243 Leukemia 0.0038
Liver neoplasms 0.1238 Colon neoplasm 0.0038
Hyperglycemia 0.1208 Gastrointestinal diseases 0.0029
Drug-induced liver injury 0.1200 Parkinson disease 0.0026
Prostatic neoplasms 0.1200 Systemic lupus erythematous nephritis 0.0026
Chronic obstructive pulmonary disease 0.0899 Glioma 0.0024
Colorectal neoplasms 0.0847 Amyotrophic lateral sclerosis 0.0022
Alzheimer disease 0.0837 Ischemia 0.0016
Type 2 diabetes mellitus 0.0814 Pulmonary emphysema 0.0013
Chronic kidney disease 0.0808 Pancreatic neoplasms 0.0013
Diabetic retinopathy 0.0805 Vascular diseases 0.0013
Huntington’s disease 0.0805 Sepsis 0.0013
Fig. 4. Systems medicine view of NRF2 from the perspective of the human interactome. Diseases are triggered by mutations that perturb proteins and
their interactions, affecting a certain neighborhood in the NRF2 interactome. Interactome-based proximity measures the distance of genes to those
disease neighborhoods. The bars show the proximity of NRF2 gene (NFE2L2) to known disease genes that participate in NRF2-related
pathophenotypes. These bars highlight the role of NRF2 in digestive system diseases and cancers. For a given disease, the proximity first calculates the
distance from NRF2 to the closest known disease gene and then compares that distance to a random expectation that is estimated using average
distances between randomly selected proteins in the interactome. The z-score reported by interactome-based proximity corresponds to the significance
of the observed distance between NRF2 and the disease genes. A negative value indicates that the observed distance is lower than what would be
expected by chance. The bars are colored in varying tones of orange based on the z-score: significantly proximal (dark orange), proximal (orange), not
proximal (light orange), respectively. The known disease genes are taken from DisGeNet, OMIM, and GWAS Catalog.
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response to tissue damage stimulate cognate receptors
expressed by immune cells that lead to activation of IkB
kinase (IKK)b. This kinase phosphorylates IkBa, tar-
geting it for degradation and allowing nuclear trans-
location and activation of NF-kB (Napetschnig and Wu,
2013). These events are submitted to redox control
through several modes of regulation of IkBa (Bowie
and O’Neill, 2000; Morgan and Liu, 2011; Siomek,
2012), but one that has been described recently involves
the regulation of IKKb stability by KEAP1. Just like
NRF2, IKKb possesses an ETGE motif that enables its
binding to KEAP for ubiquitination and proteasomal
degradation. Therefore, under basal redox conditions,
active KEAP1 targets IKKb for degradation and then
IkBa inhibits NF-kB. By contrast, in the presence of
ROS, KEAP1 is inhibited and IKKb is stabilized,
phosphorylating IkBa and leading to its degradation
and therefore to upregulation of NF-kB (Lee et al.,
2009).
Because NRF2 is a master regulator of redox homeo-
stasis, it exerts an indirect control on NF-kB activity.
Lipopolysaccharide (LPS) activates simultaneously a
fast, proinflammatory NF-kB response and a slow
NRF2 response. The NF-kB response is subsequently
inhibited when NRF2 is maximally active (Cuadrado
et al., 2014). For instance, Ras-related C3 botulinum
toxin substrate 1, a small G protein of the Rho family,
activated the NF-kB pathway and NRF2 overexpres-
sion blocked, whereas NRF2 knockdown enhanced
NF-kB–dependent transcription (Cuadrado et al.,
Fig. 5. Current status of the NRF2 diseasome. The relationships between diseases are represented as a network in which pathophenotypes are linked
by common genetic and clinical descriptors. In the figure, nodes (red hexagons) represent diseases, and the edges are similarities among them based on
shared genes, common symptoms, and comorbidities (gray, orange, and blue lines, respectively). The genes and symptoms associated with the diseases
are used to identify disease pairs that have a significant genetic and symptomatic overlap calculated using the Jaccard index. Among significant
disease–disease connections (P , 0.05, assessed by Fisher’s exact test based on the observed gene or symptom overlap), only the links that have an
elevated overlap and comorbidity are shown to eliminate potentially spurious connections. Accordingly, the diseases that share at least 10% of the
disease-associated genes and more than half of the associated symptoms are included in the figure. The comorbidity information is extracted from
medical insurance claims, representing disease pairs that tend to occur together in the population (relative risk .2).
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2014). Consistently, in NRF2-deficient (Nrf22/2) mice
challenged with LPS or tumor necrosis factor (TNF)-a,
the activity of IKKwas exacerbated and led to increased
phosphorylation and degradation of IkB (Thimmulappa
et al., 2006a).
NRF2 also induces an anti-inflammatory phenotype
thatmodulates the functions of CD8+ T cells (Sha et al.,
2015) as well as in macrophages and microglia ( Rojo
et al., 2010, 2014a; Brune et al., 2013). This is because
NRF2 increases cysteine and GSH levels in macro-
phages through regulation of the cystine/glutamate
transporter and the GSH-synthesizing enzyme
g-glutamyl cysteine ligase modulator and catalytic
subunits [g-glutamyl cysteine ligase modulator sub-
unit (GCLM) and g-glutamyl cysteine ligase catalytic
subunit (GCLC)]. Conversely, GSH depletion sensi-
tizes macrophages to NRF2 activation by LPS
(Diotallevi et al., 2017). All of these studies point to
NRF2 as an anti-inflammatory factor, crucial in con-
trolling the intensity and duration of inflammatory
responses (Fig. 6).
NRF2 and NF-kB crosstalk through feed forward and
feedback mechanisms (Fig. 7). At the transcriptional
level, NF-kB activates NRF2 expression due to the
existence of several functional binding sites in the
promoter region of the NFE2L2 gene, thus inducing a
negative feedback loop (Rushworth et al., 2012). More-
over, both NF-kB and NRF2 transcription factors re-
quire the coactivator CBP/p300, which is a histone
acetyltransferase that acetylates and increases the
DNA-binding capacity. As such, NF-kB overexpression
hampers the availability of CBP/p300 for NRF2, hence
reducing its transcriptional capacity, whereas NF-kB
knockdown shows the opposite effect (Liu et al., 2008).
Additionally, NF-kBmay promote interaction of histone
deacetylase-3 with MAF proteins, therefore preventing
their dimerization with NRF2 (Liu et al., 2008). NF-kB
binds and translocates KEAP1 to the nucleus, thus
favoring NRF2 ubiquitination and degradation in this
cellular compartment (Yu et al., 2011). The E3 ligase
adapter b-TrCP tags both IkBa (Winston et al., 1999)
and NRF2 (Rada et al., 2011, 2012; Cuadrado, 2015) for
proteasomal degradation, and therefore it can lead to
increased NF-kB activity.
The anti-inflammatory activity of NRF2 was thought
to rely only on modulation of redox metabolism or
crosstalk with NF-kB. However, NRF2 can also directly
block the transcription of the proinflammatory genes
interleukin (IL)-6 and IL-1b in macrophages upon
exposure to LPS (Kobayashi et al., 2016). LPS exposure
or pharmacological activation of NRF2 leads to its
binding to the proximal promoters of these proinflam-
matory genes and blocks the recruitment of RNA pol II.
The mechanism appears to be independent of the
binding of NRF2 to its well-established ARE enhancer.
In other studies, NRF2 could directly regulate the
expression of several other macrophage-specific genes,
such as macrophage receptor with collagenous struc-
ture, a receptor required for bacterial phagocytosis, or
CD36, a scavenger receptor for oxidized low-density
Fig. 6. Direct and indirect regulation of inflammation by NRF2. Direct mechanisms of action include transcriptional induction of anti-inflammatory
genes as well as transcriptional repression of proinflammatory genes. In the second case, the quotation mark indicates that further work is required to
identify the bZip partner of NRF2 in this function, if any. Indirect mechanisms to counteract inflammation involve ROS/RNS modulation and inhibition
of migration/infiltration of immune cells. Overall, these pathways lead to an anti-inflammatory response that helps to properly resolve inflammation.
The existence of polymorphisms in NFE2L2 associated with reduced transcriptional activity, the altered levels of target genes in patients, and
promising data from preclinical studies support a relevant role of NRF2 in inflammation resolution.
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lipoprotein (Harvey et al., 2011; Ishii and Mann, 2014).
Similarly, the gene encoding the proinflammatory
cytokine, IL-17D, contains AREs, and this NRF2–T
helper (Th)17 axis seems to confer protection against
tumorigenesis and viral infections (Saddawi-Konefka
et al., 2016).
Chronic inflammatory processes involve adhesion of
leukocytes to the vascular endothelium and infiltration
into the damaged tissue. Both processes appear to be
modulated by NRF2 together with at least one of its
target genesHMOX1, coding heme oxygenase-1 (HO-1).
The NRF2/HO-1 axis inhibits adhesion of inflammatory
Fig. 7. Crosstalk between NF-kB and NRF2 occurs at different levels. (A) Responsive elements have been identified in the promoter region ofNFE2L2.
(B) Both NRF2 and NF-kB transcription factors compete for binding to the transcriptional coactivator CREB-binding protein (CBP/p300). (C) The
NF-kB activating kinase IKKb contains an ETGE motif allowing KEAP1 binding and subsequent ubiquitin–proteasome degradation. (D) NF-kB was
reported to bind and translocate KEAP1 to the nucleus, thereby promoting NRF2 degradation. (E) ROS produced during inflammation activate NF-kB
and NRF2; finally, NRF2 attenuates ROS and consequently NF-kB activity. (F) Different proinflammatory signals activate the Rho GTPase RAC1,
which leads to NF-kB and NRF2 activation. Then NRF2 inhibits RAC1-mediated activation of NF-kB.
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cells to the endotheliumbymodulating the expression of
several cell adhesion molecules such as vascular cell
adhesion molecule 1 (Banning and Brigelius-Flohe,
2005; Wenzel et al., 2015). Additionally, NRF2/HO-1
inhibits metalloproteinase-9 in macrophages that are
necessary for migration of immune cells within tissues
(Bourdonnay et al., 2009).
Numerous preclinical studies have reported that
activation of NRF2 by natural compounds (Satoh
et al., 2013) or by disrupting its negative regulator
KEAP1 leads to potent anti-inflammatory effects in
myeloid leukocytes (Kong et al., 2011) andmacrophages
(Lin et al., 2008). In observational studies, a poly-
morphism in NFE2L2 was associated with reduced
transcriptional activity correlating with increased risk
of inflammatory bowel disease (Arisawa et al., 2008b)
and chronic gastritis (Arisawa et al., 2007). One exam-
ple of the immune modulatory action of NRF2 is
provided in the central nervous system. Injured neu-
rons release fractalkine, a chemokine that specifi-
cally activates the phosphatidylinositol 3 kinase/AKT
(PI3K/AKT) pathway in microglia, resulting in inhibi-
tion of GSK-3b and upregulation of NRF2 (Lastres-
Becker et al., 2014). In this study, necropsies from AD
and progressive supranuclear palsy patients exhibited a
compensatory increase in fractalkine levels together
with upregulated NRF2 protein, suggesting that this
pathway contributes to limiting the inflammatory re-
sponse in the diseased brain.
B. Nuclear Factor (Erythroid-Derived 2)–Like 2 in
Autoimmune Diseases
At the periphery of the NRF2 diseasome cluster, we
found several autoimmune disease phenotypes, such as
vitiligo, asthma, multiple sclerosis (MS), and systemic
lupus erythematosus (SLE). Indeed, extensive work in
animal models of experimental autoimmune encepha-
lomyelitis (EAE) and rheumatoid arthritis (RA), as well
as clinical evidence inMS and psoriasis further points to
a role of NRF2 in autoimmune diseases. Oxidative
tissue damage and apoptosis may increase the genera-
tion of autoantigens, leading to activation of T cells and
production of autoantibodies by B cells, e.g., as observed
for 3-nitrotyrosine–positive proteins (Thomson et al.,
2012). In addition, loss of phase II detoxification
enzymes, many of which are transcriptionally regulated
by NRF2, results in increased production of reactive
intermediates that contribute to formation of haptens or
damaged macromolecules that sometimes become im-
munogenic, increasing hence the pool of autoantigens
that trigger autoimmune reactions. Because NRF2-
regulated enzymes play a critical role in the detoxifica-
tion of many chemicals, it is conceivable that NRF2
may be a protective mechanism against the environ-
mental contribution to autoimmune pathogenesis (Ma,
2013). Potential mechanisms for NRF2-mediated regu-
lation of autoimmunity also involve suppression of
proinflammatory Th1 and Th17 responses and activa-
tion of immunosuppressive T regulatory (Treg) and Th2
ones. There is also increasing evidence that NRF2 may
control the differentiation and function of dendritic cells
(DCs) and macrophages involved in antigen presenta-
tion and regulation of adaptive immune responses. In
fact, NRF2 deficiency was shown to alter the function
and phenotype of DCs by increasing the expression of
costimulatory molecules and consequently the antigen-
specific T cell reactivity (Al-Huseini et al., 2013).
MS is a chronic inflammatory disease characterized
by infiltration of autoreactive immune cells into the
central nervous system. The absence of NRF2 exacer-
bates the development of EAE, which is a mouse model
of MS (Johnson et al., 2010). Part of the effects
associated with NRF2 deficiency may be related to the
reduced levels of HO-1. Thus, mice with a myeloid-
specific HO-1 deficiency exhibited higher incidence of
lesions, accompanied by activation of antigen-
presenting cells and infiltration of inflammatory Th17
and myelin-specific T cells (Tzima et al., 2009). Knock-
down of KEAP1 (Kobayashi et al., 2016) or treatment
with a wide range of small molecules that activate
NRF2 (Buendia et al., 2016) inhibited the development
and severity of disease. NRF2 is strongly upregulated
in active MS lesions, and the expression of NRF2-
responsive genes is predominantly found in areas of
initial myelin destruction (Licht-Mayer et al., 2015). In
MS brains, NRF2 and its targets NADPH:quinone
oxidoreductase (NQO1) and HO-1 are mainly expressed
in infiltrating macrophages and to a lesser extent in
astrocytes, most likely as a compensatory response
against pathologic ROS formation. In contrast, there
is a lack of NRF2 and antioxidant gene expression in
oligodendrocytes, and this may underlie their damage
and loss in MS (van Horssen et al., 2010). As a
consequence of the altered immune and redox homeo-
stasis, HO-1 expression is reduced in peripheral blood
mononuclear cells of MS patients and is downregulated
during exacerbation of the disease (Fagone et al., 2013).
Of note, gene expression profiling in interferon-b–treated
patients identified NRF2 as a potential mediator of long-
term antioxidant response and neuronal preservation
(Croze et al., 2013).
SLE is underlined by high oxidative environment,
deregulated cell death, and defects in removal of dead
cells, which leads to cell necrosis as source of autoan-
tigens. Female mice deficient in NRF2 develop with
age amultiorgan autoimmune disorder similar to SLE,
characterized by increased DNA oxidation, lipid per-
oxidation, splenocyte apoptosis, presence of antibodies
against double-strand DNA and the Smith antigen,
along with important tissue damage (vasculitis, glo-
merulonephritis, hepatitis, and myocarditis) (Li et al.,
2004). The fact that only female mice show progression
to SLE suggests that female-specific factors may
contribute to break immune tolerance to self-antigens
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(Li et al., 2004). NRF2 deficiency also results in
enhanced proliferative responses of CD4+ T cells,
altered CD4+/CD8+ ratio, and promotion of proinflam-
matory Th17 in SLE (Ma et al., 2006; Zhao et al., 2016).
In fact, NRF2 depletion has been associated with Th17
differentiation and function during development of
lupus nephritis, which seems to be mediated by regu-
lation of the suppressor of cytokine signaling 3/phos-
phorylated signal transducer and activator of
transcription (STAT)3 pathway and IL-1b signaling
(Zhao et al., 2016). In addition, the salivary glands of
Nrf22/2 mice show intense lymphocyte infiltration,
reminiscent of the Sjögren syndrome, which is often
associated with SLE (Ma et al., 2006). SLE patients
exhibit alterations in repair mechanisms of oxidative
DNA damage (Evans et al., 2000), high serum levels of
oxidized proteins, apolipoprotein C3 (Morgan et al.,
2007), oxidized phospholipids, and autoantibodies
against oxidatively modified lipoproteins (Frostegard
et al., 2005). NRF2 polymorphisms have not been
associated with SLE susceptibility, although the SNP
rs35652124 was related to increased risk of nephritis
in childhood onset of Mexican females (Cordova et al.,
2010).
Rheumatoid arthritis (RA) is a systemic inflamma-
tory disease with a complex but still elusive autoim-
mune profile, in which neutrophils, macrophages,
and lymphocytes are actively recruited and activated
in the inflamed joints. This results in increased secre-
tion of proinflammatory mediators such as ROS/RNS,
eicosanoids, cytokines (IL-17, TNF-a, interferon-g, IL-6,
and IL-1b), and catabolic enzymes that trigger hyper-
proliferation of synovial fibroblasts, joint swelling, and
progressive destruction of cartilage and bone (Roberts
et al., 2015). Deletion of the NRF2 gene increases
vulnerability to joint alterations in experimental RA
models. For instance, in mice expressing the T cell
receptor KRN and themajor histocompatibility complex
class IImolecule A(g7) (theK/BNarthritismodel), and
in antibody-induced arthritis, NRF2 deficiency acceler-
ates the incidence and aggravates the disease course
(Maicas et al., 2011; Wu et al., 2016b). NRF2 deficiency
dramatically upregulates migration of inflammatory
cells, expression of cyclooxygenase-2 and inducible
nitric oxide synthase, production of ROS and RNS,
and release of proinflammatory cytokines and chemo-
kines. Moreover, NRF2 may be a protective factor for
bone metabolism in arthritis (Maicas et al., 2011), and
NRF2/HO-1 activation exerts anti-inflammatory and
antioxidant effects in animal models of RA and in
human synovial fibroblasts (Wu et al., 2016b). It is
interesting that antirheumatic gold(I)-containing com-
pounds that stimulate the antioxidant response
through activation of NRF2 and upregulation of HO-1
and GCLC proved clinical efficacy in RA (Kobayashi
et al., 2016). Moreover, NRF2/HO-1 activationmediates
the induction of synovial cell apoptosis and inhibition of
proinflammatory cytokine production by cilostazol
(Park et al., 2010) as well as the anti-inflammatory
effects of H2S and related compounds, which are able to
modify by sulfhydration the cysteine residues of KEAP1
(Wu et al., 2016b). Other drugs that induce NRF2 and
HO-1 signaling, such as rebamipide, can divert the
differentiation of human and murine CD4+ T cells
toward an immunosuppressive Treg phenotype and
inhibit the differentiation of TCD4+ cells toward in-
flammatory Th17 cells through specific inhibition of
STAT3 (Moon et al., 2014). Excessive ROS generation
within the inflamed synovium appears to contribute to
the pathogenesis of RA because patients show amarked
increase in ROS formation, lipid peroxidation, protein
oxidation, DNA damage, and decrease in the activity of
the antioxidant defense mechanisms, all of these con-
tributing to tissue damage and disease progression
(Datta et al., 2014). In response to pathologic ROS
formation, the NRF2 pathway is activated in synovial
cells of RA patients and in joints of antibody-induced
arthritic mice, but this response is apparently insuffi-
cient to counteract the disease progression (Wu et al.,
2016b).
Vitiligo is a skin inflammatory disorder characterized
by the accumulation of ROS in the epidermis, which
participates in the death of melanocytes. These mole-
cules modify DNA and melanosomal proteins with
formation of autoantigens and activation of an autoim-
mune response against melanocytes (Xie et al., 2016).
Genetic studies have revealed associations of NRF2
promoter SNPs with susceptibility to develop vitiligo,
such as the SNP at 2650 position (Guan et al., 2008),
whereas the C allele of rs35652124 was shown to be
associated with protective effects in a Han Chinese
population (Song et al., 2016). NRF2 and its down-
stream detoxification target genes NQO1, GCLC, and
GCLM are upregulated in the epidermis of vitiligo
patients, suggesting insufficient activation of this de-
fensive mechanism (Natarajan et al., 2010).
C. Nuclear Factor (Erythroid-Derived 2)–Like 2 in
Chronic Respiratory Diseases
The relevance of NRF2 in respiratory diseases was
reviewed in 2010 (Cho and Kleeberger, 2010), and in
this work we will highlight only the most relevant
findings (Fig. 8). Cigarette smoke is a main risk factor
for chronic obstructive pulmonary disease (COPD).
COPD patients have dysfunctional alveolar macro-
phages that lead to uncontrolled ROS production,
proinflammatory mediators, defective phagocytosis,
and an array of metalloproteinases that participate in
tissue damage. In fact, the emphysematous lung tissue
shows a direct correlation between alveolarmacrophage
density in the parenchyma and severity of lung de-
struction (Finkelstein et al., 1995). Impaired phagocytic
activity of alveolar macrophages is a major cause of
recurrent bacterial and viral infections that cause acute
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exacerbations of COPD and are a major source of
morbidity and mortality. Nrf22/2 mice exhibit en-
hanced susceptibility to cigarette smoke-induced em-
physema (Rangasamy et al., 2004). Importantly,
activation of NRF2 with the isothiocyanate sulfora-
phane (SFN) restores bacteria recognition and phago-
cytosis, enhances pulmonary bacterial clearance by
alveolar macrophages, and reduces inflammation in
wild-type mice, but not in Nrf22/2 mice exposed to
cigarette smoke (Harvey et al., 2011). In humans, the
transcriptional signature of NRF2 is decreased in
alveolar macrophages from patients with smoking-
related lung emphysema as compared with smoking
and nonsmoking patients without emphysema (Goven
et al., 2008). Decreased NRF2 expression is associ-
ated with increased macrophage expression of the
lipid peroxidation product 4-hydroxynonenal. In the
NFE2L2 promoter, a functional haplotype constituted
by three SNPs and one triplet repeat, polymorphism
that produces low to medium NRF2 expression
(Yamamoto et al., 2004), was associated with in-
creased risk to develop COPD (Hua et al., 2010). The
low-expressing haplotypes were significant predictors
for developing respiratory failure. Thus, the 2617A
allele of SNP rs6721961 had a significantly higher risk
for developing acute lung injury (Marzec et al., 2007).
Pathologic ROS formation may play a role in the
pathogenesis of chronic lung fibrosis. An early study
demonstrated that pulmonary fibrosis induced by bleo-
mycin is more severe in Nrf22/2 than in wild-type mice
(Cho et al., 2004). In fact, wild-type mice induced an
antioxidant and anti-inflammatory response by upre-
gulating NRF2, and this could not be achieved in the
Nrf22/2 mice. Later, it was verified that patients with
idiopathic pulmonary fibrosis or chronic sarcoidosis/hy-
persensitivity pneumonitis exhibit increased expres-
sion of NRF2 and augmented levels of low-mol. wt.
antioxidants in bronchoalveolar lavage fluids, such as
uric acid, ascorbic acid, retinol, and a-tocopherol,
suggesting an unsuccessful adaptive response to the
ROS challenge (Markart et al., 2009). Mechanistically,
NRF2 deficiency increases myofibroblast differentia-
tion, whereas pharmacological induction of NRF2 with
SFN results in lower number of myofibroblasts and
Fig. 8. Role of NRF2 in common mechanisms and pathophenotypes of chronic diseases. The picture provides some examples extracted from the NRF2
diseasome cluster of Fig. 5. Common pathomechanisms of these diseases include abnormally high ROS levels and low-grade chronic inflammation that
participate in tissue damage. NRF2 provides a cytoprotective signature against these and other tissue-specific alterations by regulating the expression
of numerous cytoprotective genes.
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attenuation of the profibrotic effects of transforming
growth factor-b (TGF-b) (Artaud-Macari et al., 2013).
D. Nuclear Factor (Erythroid-Derived 2)–Like 2 in the
Digestive System
The prominent position of pathophenotypes of the
digestive system in the NRF2 diseasome highlights the
relevance of the transcriptional signature of NRF2 as a
potent adaptive mechanism to chronic oxidative dam-
age and inflammatory stress triggered by xenobiotics.
In the gastrointestinal tract (GI), chronic exposure to
xenobiotics triggers dysfunctional interactions between
the microbiota of the intestinal lumen and the immune
system (Aviello and Knaus, 2017). This can lead to
chronic diseases of the GI tract, like the inflammatory
bowel disease (IBD) phenotypes comprising Crohn’s
disease and ulcerative colitis, in which there is evidence
of activation of a protective NRF2 response. For in-
stance, in colonic tissues from IBD patients, colon
epithelial cells responded to inflammatory signals
through a NRF2-dependent adaptation that was asso-
ciated with increased proteasome protein expression
(Kruse et al., 2016). Monocyte-derived macrophages
from IBD patients evidenced a specific NRF2-
dependent gene expression profile that was exacerbated
in response to LPS, further suggesting an attempt to
attenuate the inflammatory challenge (Baillie et al.,
2017). At the genetic level, a particular genotype of the
NFE2L2 gene (26862684) was associated with the
development of ulcerative colitis, especially in females,
in a Japanese cohort (Arisawa et al., 2008a). In fact,
pathologic processes in the GI are highly dependent on
the genetic background of the host in relation with
dysfunctional interaction between the microbiota of the
intestinal lumen and the immune system (Aviello and
Knaus, 2017).
One of the symbiotic effects of themicrobiota of theGI is
to release moderate amounts of ROS that elicit a cytopro-
tective response mediated by NRF2 in epithelial colono-
cytes and infiltrating immune cells (Jones et al., 2015).
Moreover, cytoprotective molecules that are under the
transcriptional control of NRF2 in eukaryotes can also be
produced by commensal bacteria. For instance, the HO-1
homologs in the microbiota may greatly contribute to GI
homeostasis, and this can be therapeutically exploited for
local delivery of carbonmonoxide to the intestine (Onyiah
et al., 2014).
The proven involvement of NRF2 in maintaining GI
homeostasis makes this transcription factor a promising
therapeutic target in IBD. Thus, several chemical com-
pounds and dietary supplementsmight exhibit beneficial
effects, like melatonin, 3-(3-pyridylmethylidene)-2-
indolinone, butyrate, Lactobacillus casei, L-carnitine,
4-vinyl-2,6-dimethoxyphenol (canolol), lacto-wolfberry
(formulated product of wolfberries in skimmed milk),
etc. (Orena et al., 2015). Therefore, it is of utmost
importance to define the involvement of NRF2 in chronic
and acute diseases of the GI tract for better guidance on
the therapeutic approach for modulating the NRF2
pathway.
The liver is also a first line of defense against food
xenobiotics. Therefore, it is not surprising that the
NRF2 diseasome highlights the relevance of this tran-
scription factor in pathophenotypes associated with liver
damage. Early work with the Nrf22/2 mouse model
demonstrated its protective effect against acetaminophen-
induced hepatocellular injury, benzo[a]pyrene-induced
tumor formation, and Fas- and TNF-a–mediated hepato-
cellular apoptosis (Aleksunes and Manautou, 2007). The
higher sensitivity of Nrf22/2 mice to chemical toxicity
correlated with reduced basal and inducible expression of
detoxification enzymes. In humans, the functional haplo-
type of three NRF2 promoter SNPs that result in reduced
NRF2 expression was significantly associated with devel-
opment of gastric mucosal inflammation, either indepen-
dently or by interacting with Helicobacter pylori infection
(Arisawa et al., 2007). Analysis of the transcriptional
signature of NRF2 in patients with primary biliary
cholangitis indicated that these patients exhibit reduced
NRF2 expression together with low levels of HO-1 and
GCLCproteins, and these impairments aremore advanced
in patients with cirrhosis (Wasik et al., 2017).
Pathologic ROS formation is a key mechanism of
hepatocellular injury and disease progression in pa-
tients with nonalcoholic steatohepatitis (NASH) (Fig.
8). This disease evolves in two phases, one of progressive
accumulation of fatty acids in hepatocytes and a second
that involves liver injury and inflammatory pathologic
ROS formation (Wang et al., 2018). Accordingly, mice
fed with a high-fat diet (HFD) developed a simple
steatosis, characterized by increased hepatic fat de-
position without inflammation or fibrosis, but Nrf22/2
mice presented exacerbated hepatic steatosis and sub-
stantial inflammation, consistent with NASH (Reccia
et al., 2017). It is interesting, however, that the
hepatocyte-specific KEAP1 deletion, while reducing
liver steatosis, did not alter inflammation during devel-
opment of NASH, suggesting a compensatory mecha-
nism (Ramadori et al., 2016). At least in the rat model of
NASH, dietary NRF2 activators attenuate the progres-
sion of liver fibrosis (Shimozono et al., 2013). Markers of
pathologic ROS formation were increased in liver bi-
opsies of NASH patients, and the NRF2 signature was
increased, suggesting an attempt to reduce the oxidant
and inflammatory burden (Takahashi et al., 2014).
E. Nuclear Factor (Erythroid-Derived 2)–Like 2 in the
Cardiovascular System
The NRF2 diseasome cluster points to the high
susceptibility of the cardiovascular system to changes
in the cellular redox balance and the development of
well-known comorbidities like atherosclerosis, hyper-
tension, and diabetes (Griendling and FitzGerald,
2003a,b; Harrison et al., 2003; Jay et al., 2006)
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(Fig. 8). A role of NRF2 in preventing these pathophe-
notypes has been demonstrated inNrf22/2mice, which
exhibit impaired cardiac structure (more remodeling
events) and function (less fractional shortening) in
response to chronic endurance exercise (Shanmugam
et al., 2017a). They are also more susceptible to develop
heart failure after myocardial infarction (Strom and
Chen, 2017). In contrast, constitutive activation of
NRF2 creates a reductive state, characterized by in-
creased cardiac GSH/glutathione disulfide ratio and
decreased ROS formation and malondialdehyde levels
(Shanmugam et al., 2017b). In humans, microarray
analysis in Tako–Tsubo cardiomyopathy indicated an
increase in pathologic ROS levels and a compensatory
upregulation of NRF2 during the acute phase of this
contractile dysfunction (Nef et al., 2008). Recently,
systemic inflammation and pathologic ROS formation
in hemodialysis patients were associated with down-
regulation of NRF2 (Pedruzzi et al., 2015), and two
promoter polymorphisms (rs35652124 and rs6721961)
were associatedwith increased risk ofmortality in these
patients (Shimoyama et al., 2014).
One of the most relevant targets of NRF2 in endothe-
lial homeostasis is HO-1, which is usually paralleled by
upregulation of ferritin, hence decreasing free iron
levels and preventing Fenton-type reactions. Bilirubin,
which is generated from the combined activity of HO-1
and biliverdin reductase, is one of the most powerful
endogenous antioxidants that scavenges ROS/RNS
(Jansen et al., 2010), and is highly efficient in prevent-
ing lipid peroxidation in vitro (Stocker et al., 1987).
Hmox12/2 mice show increased pulmonary hyperten-
sion in response to chronic hypoxia (Christou et al.,
2000), and pharmacological HO-1 induction improves
diabetic complications (Kruger et al., 2006), as well as
nitroglycerin-induced vascular dysfunction (nitrate tol-
erance) (Wenzel et al., 2007). Recently,Hmox12/2mice
were shown to display upregulated NADPH oxidase-2,
vascular pathologic ROS formation, markers of inflam-
mation, endothelial dysfunction, and higher blood pres-
sure in response to angiotensin-II (Wenzel et al., 2015).
In fact, high serum levels of bilirubin are inversely
correlated with the incidence of coronary artery disease
(Hopkins et al., 1996). Bilirubin prevents the activation
of the vascular NADPH oxidase (Kwak et al., 1991),
involved in the development of cardiovascular diseases
(Griendling and FitzGerald, 2003a,b; Harrison et al.,
2003; Jay et al., 2006). Patients suffering from periph-
eral artery disease, which is a common manifestation
of atherosclerosis, present reduced levels of HO-1
(Signorelli et al., 2016).
F. Nuclear Factor (Erythroid-Derived 2)–Like 2 in
Metabolic Diseases
Type 2 diabetes mellitus (T2DM) is one of the most
common chronicmetabolic diseases and is highly under-
lined in theNRF2 diseasome. Pathologic ROS formation
in insulin-sensitive tissues, as well as in pancreas, has
been found in T2DM patients, resulting in severe
impairment of both insulin secretion by pancreatic b
cells and insulin action in peripheral tissues (Uruno
et al., 2015) (Fig. 8). Likewise, pathologic ROS levels
also contribute to the pathogenesis of diabetic compli-
cations due to nonenzymatic glycation of proteins. This
has been evidenced in diabetic nephropathy, in which
the glomeruli exhibit pathologic ROS levels and a
compensatory elevation of NRF2 (Jiang et al., 2010).
Since 2007, several studies have addressed the role of
NRF2 in T2DM and its complications using animal
models and cell lines. In vitro studies in human cells
reported that NRF2 activation is achieved with acute
exposure to high glucose, whereas longer incubation
times or oscillating glucose concentration failed to
activate NRF2 (Ungvari et al., 2011; Liu et al., 2014).
Accordingly, these studies pointed out that NRF2
activation is dependent on glucose concentration and
dynamics. In contrast, NRF2 is downregulated in
peripheral blood mononuclear cells of prediabetic and
diabetic patients, suggesting that NRF2 could be an
important therapeutic target (Jimenez-Osorio et al.,
2014).
The impact of NRF2 deficiency on hyperglycemia was
first shown in Nrf22/2mice, where oxidative and nitro-
sative alterations were enhanced and led to early-stage
renal injury (Yoh et al., 2008). In a subsequent study,
streptozotocin-induced diabetic Nrf22/2 mice exhibited
exacerbated glomerular injury, together with high ROS
production and increased expression of the profibrotic
markers TGF-b and fibronectin (Jiang et al., 2010).
In this diabetic model, NRF2 protected against dys-
function of the blood–retina barrier and the progres-
sion of diabetic retinopathy (Xu et al., 2014). Likewise,
HFD-induced increase in vascular ROS levels was signif-
icantly exacerbated inNrf22/2mice andwas accompanied
by a severe endothelial dysfunction, as shown by
diminished acetylcholine-induced relaxation of aorta
and increased expression of intercellular adhesion
molecule-1 and TNF-a (Ungvari et al., 2011).
NRF2 plays a complex role in tissue-specific insulin
resistance. Thus, HFD-fed Nrf22/2 mice displayed
better insulin sensitivity due to enhanced insulin
signaling in liver and skeletal muscle than their wild-
type counterparts, but conversely, these mice developed
a severe NASH due to excessive hepatic lipotoxicity
linked to pathologic ROS formation (Meakin et al.,
2014). Accordingly, this study dissociated hepatic in-
sulin resistance from the development of NASH. In light
of these data, a subsequent study demonstrated that the
livers of HFD-fed Nrf22/2 mice exhibited higher path-
ologic ROS formation by a significant depletion of GSH
due to attenuated expression of the CYP2A5 enzyme
(Cui et al., 2013). The knockdown of NRF2 in hepato-
cytes enhanced the apoptosis induced by palmitate, a
fatty acid that is highly elevated in insulin-resistant
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obese patients. This effect was correlated with in-
creased production of pathologic ROS, again reinforcing
the key role of NRF2 in the progression of NASH (Pilar
Valdecantos et al., 2015).
To further examine the role of NRF2 in the metabolic
syndrome, NRF2 was ablated in leptin-deficient (ob/ob)
mice, a model with an extremely positive energy balance
(Xue et al., 2013). Interestingly, global ob/ob/Nrf22/2mice
or adipocyte-specific ob/ob/Nrf22/2micedisplayed reduced
white fat mass, revealing NRF2 as a key player in
adipogenesis. These mice had an even more severe
metabolic syndrome that was characterized by hyper-
lipidemia, aggravated insulin resistance, and hyper-
glycemia, suggesting a mechanistic linkage between
the metabolic syndrome and pathologic ROS formation.
Another subset of studies has evaluated the effects of
persistent induction of NRF2 in glucose metabolism.
Genetic NRF2 induction making use of a hypomorphic
allele of Keap1 (Keap1flox/- mutant) decreased blood
glucose in the obese diabetic db/db mice by suppressing
hepatic glucose 6 phosphatase through the repression of
cAMP-CREB signaling in hepatocytes, as well as other
gluconeogenic genes, such as peroxisome proliferator-
activated receptor coactivator-1a (Uruno et al., 2013).
Additionally, enhancement of NRF2 activity in Keap11-
knocked down mice increased the phosphorylation of
AMP-activated protein kinase (AMPK) in the liver, as
well as insulin signaling in skeletal muscle, resulting in
a substantial improvement of glucose tolerance (Xu
et al., 2013). Due to the pleiotropic activities of NRF2 in
the context of T2DM, the results of all these and other
studies have evidenced the need to design multiple
genetic and pharmacological strategies to elucidate the
full array of NRF2 functions in tissues involved in the
control of whole-body glucose homeostasis.
In addition to diabetic factors like age, body weight,
and blood glucose, genetic factors that are linked to
NRF2 have been poorly studied in humans. In aChinese
population, the SNP rs6721961 has been associated
with pathologic ROS formation and risk of newly di-
agnosed T2DM and may also contribute to impaired
insulin secretory capacity and increased insulin re-
sistance (Wang et al., 2015). The same SNP was
associated with diabetes in Mexican mestizo men
(Jimenez-Osorio et al., 2017). In a case-control study
performed with Han volunteers, a significant difference
in genotypic and allelic frequencies of four SNPs of the
NFE2L2 gene was found between T2DM patients with
and without complications, including peripheral neu-
ropathy, nephropathy, retinopathy, foot ulcers, and
microangiopathy (Xu et al., 2016b).
G. Nuclear Factor (Erythroid-Derived 2)–Like 2 in
Neurodegenerative Diseases
The NRF2 diseasome provides evidence of NRF2
involvement in several neurodegenerative diseases,
including AD and PD, which represent the most
prevalent cognitive and motor disorders of the elderly.
In neurodegenerative diseases, the connection be-
tween low-grade pathologic ROS formation and proteo-
stasis is particularly relevant because most of these
pathophenotypes are characterized by abnormal ag-
gregation of specific proteins (Fig. 8). Evidence point-
ing to pathologic ROS formation in proteinopathy, as
well as NRF2 as regulator of proteasome and auto-
phagy was provided in cellular and animal models
(Pajares et al., 2017). Initially, it was reported that the
autophagy cargo protein sequestosome 1 (SQSTM1)
competes with NRF2 for binding to KEAP1. SQSTM1
takes KEAP1 to the autophagosome degradative path-
way, therefore upregulating NRF2 (Komatsu et al.,
2010). More recently, it was found that NRF2 regulates
the expression of autophagy genes involved in auto-
phagy initiation, cargo recognition, elongation, and
autolysosome clearance (Pajares et al., 2016). In this
study, amyloidopathy and tauopathy induced by trans-
gene overexpression of human mutant amyloid pre-
cursor protein and tau were aggravated in Nrf22/2
mice. A connection between NRF2 deficiency and
neurodegeneration is supported by a growing body of
evidence in animal models (Johnson and Johnson,
2015). The general point of view is that damaged
neurons try to activate NRF2-dependent transcription,
presumably to increase their own survival. Addition-
ally, upregulation of NRF2 in astrocytes participates
in metabolic compensations, including increased sup-
ply of GSH for augmenting their proliferative capacity
(Bolanos, 2016), whereas NRF2 upregulation in micro-
glia returns this immune cell to a resting state (Rojo
et al., 2014a).
Ramsey et al. (2007) evidenced the nuclear localiza-
tion of NRF2 in dopaminergic neurons of patients with
PD. Other studies found that amyloid precursor
protein– and tau-injured neurons expressed increased
levels of NRF2 and its target SQSTM1, probably as
compensatory mechanism to clear these toxic proteins
through autophagy (Lastres-Becker et al., 2014; Pajares
et al., 2016). In agreement with these results, the levels
of HO-1, NQO1, GCLM, and SQSTM1 are increased in
AD and PD brains (van Muiswinkel et al., 2004;
Cuadrado et al., 2009; Schipper et al., 2009; Lastres-
Becker et al., 2016). However, there is some controversy
in the field, as Ramsey’s study described the accumula-
tion of NRF2 in the cytosol of AD-injured neurons,
suggesting an impaired capacity of these neurons to
upregulate NRF2 transcriptional activity. In addition,
the cytoprotective proteins associated with NRF2 ex-
pression, such as NQO1 and SQSTM1, were partly
sequestered in Lewy bodies, suggesting impaired neuro-
protective capacity of the NRF2 signature in PD
patients (Lastres-Becker et al., 2016). One possible
explanation for this discrepancy could be that the levels
of NRF2 and its target genes might change during
ageing and disease progression.
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Some SNP haplotypes of NFE2L2 were associated
with decreased risk or delayed onset of ALS, AD, or PD.
The onset of ALS was analyzed in two studies regarding
three functional promoter SNPs that were previously
linked to high gene expression. Interestingly, this
haplotype was associated with a 4-year delay in onset
of ALS (Bergstrom et al., 2014), but another study did
not find a clear association (LoGerfo et al., 2014).
Regarding AD, one haplotype allele was associated with
2-year earlier age onset of AD, suggesting that variants
of the NFE2L2 gene may affect AD progression (von
Otter et al., 2010b). Genetic association ofNFE2L2with
PD has been analyzed in more detail. Three SNPs in
the NFE2L2 promoter (rs6721961, rs6706649, and
rs35652124) were evidenced as protective haplotype in
a case-control study (von Otter et al., 2010a). Such
haplotype delayed the onset of disease in a Swedish
cohort or even reduced the risk of PD in a Polish cohort.
These results were supported by four new independent
European case-control studies (von Otter et al., 2014),
but were not replicated in a Taiwanese population
(Chen et al., 2013), suggesting disparity in ethnicities
and environmental factors. As an alternative approach,
PD cells derived from olfactory mucosa were exposed to
smoke extract or pesticide to assess gene–environment
interaction, and several SNPs were identified that
affect the susceptibility to these toxins (Todorovic
et al., 2015). Altogether, it is possible that a slight
activation of NRF2, such as that found for some
functional haplotypes of the NFE2L2 gene, should be
enough to trigger protective mechanisms in the brain.
IV. The Kelch-Like ECH-Associated Protein
1 Paradox in Cancer
An apparent dichotomy appears to exist in the role of
NRF2 in tumorigenesis and further tumor progression.
On one hand, by activating biotransformation reactions,
NRF2 protects against chemically induced carcinogen-
esis. Preclinical studies have demonstrated complete
protection against aflatoxin B(1)-induced liver cancer
after pharmacological activation of NRF2 in rats
(Johnson et al., 2014). In contrast, the protective
responses elicited by NRF2 provide a growth advantage
in established cancers, and this will be the focus of this
section.
Constantly increased levels of ROS can sustain
tumorigenesis through alteration of genomic stability,
along with activation of specific redox signaling circuits
and inflammatory processes that favor survival and
proliferation of tumor cells (Reuter et al., 2010). There-
fore, upregulation of NRF2 represents a mechanism of
adaptation of cancer cells to tolerate high ROS levels
that propel tumor progression (Schumacker, 2006) as
well as to maintain cancer stem cells that are respon-
sible for tumor relapse and formation of distant metas-
tases (Ryoo et al., 2016). For instance, the NRF2
signature in cancer stem cells from human colorectal
tumors pointed out protective mechanisms mediated by
high levels of GCLC, glutathione peroxidase, and
thioredoxin reductase-1 that underlie the ability of
these cells to counteract stressors and chemotherapeu-
tics (Emmink et al., 2013). From this perspective, NRF2
behaves in cancer cells like an oncogene that by in-
ducing chronic activation of ARE-mediated cytoprotec-
tive responses affords adaptation to their oxidative
environment (Panieri and Santoro, 2016). Several
mechanisms of malignant activation of NRF2 have been
reported, including somatic mutations, epigenetics, and
oncogenic signaling alterations.
Close to 600 somatic mutations have been reported
in cancer along the coding sequence of NFE2L2 (Gao
et al., 2017). In Fig. 9, we show the results from a
dataset of 10,000 cancer patients (Zehir et al., 2017). In
most cases, these mutations alter the interaction of the
DLG and ETGE motifs of NRF2 with KEAP1, hence
inducing hyperactivation of NRF2 in several solid
tumors, including esophagus, skin, lung, and larynx
carcinomas (Kim et al., 2010b; Taguchi and Yama-
moto, 2017). For instance, in advanced esophageal
squamous cancer, gain-of-function mutations of
NRF2 were associated with tumor recurrence and poor
prognosis due to increased proliferation, attachment-
independent survival, and resistance to chemo- and
radiotherapy (Shibata et al., 2011). Loss-of-function
mutations in the KEAP1 gene are also frequent in some
solid tumors such as lung cancer (Singh et al., 2006).
Based on the strong evidence that this pathway regu-
lates b-TrCP/NRF2, it is strange that disrupting so-
matic mutations have not been found at the interface
between NRF2 and b-TrCP. This fact suggests that
such mutations are not viable for unknown reasons or
that the increase in NRF2 levels that would result
from the escape of b-TrCP is not sufficient to drive
oncogenicity.
Nonetheless, somatic mutations account for chronic
NRF2 activation only in a fraction of cancer patients. At
the level of gene expression, it is interesting that an
allele of the SNP rs6721961 (2617C. A) located at the
ARE enhancer of the human NRF2 gene abolished self-
induction of NRF2, and this correlated with remarkable
survival of these cancer patients (Okano et al., 2013).
Epigenetic changes due to promoter hypermethylation
of three CpG sites ofKEAP1 have been described in lung
tumors, resulting in consequent NRF2 activation that
could be reversed by 5-aza-29-deoxycitydine treatment
(Wang et al., 2008). The role of miRNAs in the post-
transcriptional regulation of NRF2 levels has been
reviewed recently (Kurinna and Werner, 2015). Briefly,
miR200a targets the KEAP1 mRNA in human breast
cancer cells, leading to its degradation and consequent
activation of NRF2 (Eades et al., 2011). In turn, miR28
facilitates the degradation of the NRF2 mRNA (Yang
et al., 2011).
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Oncogenes or mutated tumor suppressors may en-
hance the activation of NRF2 in cancer. Endogenous
oncogenic alleles of KRAS, BRAF, or c-MYC upregulate
NRF2, presumably through oncogene-mediated ROS
generation and consequent chronic inactivation of
KEAP1 (DeNicola et al., 2011). The mutated form of
the tumor suppressor p53, which sustains the growth of
cancer cells by enhancing nutrient uptake and synthesis
of building blocks, can also upregulate NRF2, possibly
through the crosstalk with the Sp1 transcription factor
that binds to the NRF2 promoter (Tung et al., 2015).
The phosphorylation of NRF2 (phospho-NRF2) by
various protein kinases is a potential mechanism of
activation in 107 hepatocellular carcinomas. Increased
levels of phospho-NRF2 were associated with reduced
KEAP1 expression and poor 5-year overall survival of
patients exhibiting this distinctive phenotype (Chen
et al., 2016). Additionally, mutations in the phosphatase
and tensin homolog (PTEN) tumor suppressor sustain
hyperactive and oncogenic phosphatidylinositol-3-kinase
(PI3K)–AKT signaling and consequent increase in NRF2
activity due to the downregulation of the PTEN/GSK-3/
b-TrCP pathway for the proteasomal degradation of
NRF2 (Rada et al., 2011, 2012; Cuadrado, 2015). Thera-
peutic interventions targeting the PTEN/GSK-3/b-TrCP
pathway should take into consideration that GSK-3 may
act both as tumor suppressor and tumor promoter, and is
also implicated in the generation of cancer stem cells
(McCubrey et al., 2014).
Some stress-induced proteins interact with KEAP1
and thus compete with its NRF2 binding in cancer cells.
Consequently, NRF2 escapes KEAP1-mediated degra-
dation. One of theNRF2 competitors for KEAP1 binding
is the phosphorylated form of the autophagy-adaptor
protein SQSTM1 that occurs during selective auto-
phagy used by cancer cells for sustaining their own
growth (Shimizu et al., 2016). The cyclin-dependent
kinase inhibitor p21 that promotes cell cycle arrest in
cancer stem cells was also demonstrated to inhibit the
association of NRF2 with KEAP1 through the interac-
tion of its KRR motif with DLG and ETGE motifs in
NRF2 (Chen et al., 2009). Recently, it was shown that
dipeptidyl-peptidase 3, which bears an ETGE motif,
may compete with NRF2 for binding to KEAP1 (Hast
et al., 2013). Overexpression of dipeptidyl-peptidase 3,
possibly induced by chronic alteration of the redox
status, correlates with increased expression of ARE
genes and poor prognosis, particularly in estrogen
receptor–positive breast cancer (Lu et al., 2017).
NRF2 induces metabolic changes that contribute to
cancer progression. For instance, a multiplatform non-
targeted metabolomics study identified patterns of
metabolite changes in breast tumor samples (Tang
et al., 2014). They found that GSH and 3-(4-
hydroxyphenyl)lactate were positively correlated with
the involvement of BRCA1 in redox homeostasis
through interaction with NRF2. Metabolomics studies
also indicate that NRF2 can increase aerobic glycolysis
in cancer cells to support their high-energy require-
ments. This occurs through NRF2-mediated induction
of Mn-superoxide dismutase expression, leading to
elevatedmitochondrial production of hydrogen peroxide
Fig. 9. Somatic mutations found in tumors of the MSK-IMPACT Clinical Sequencing Cohort (MSKCC) study (Zehir et al., 2017) and pharmacologic
strategies to inhibit NRF2. (A) Percentage of tumors with NRF2 mutations. (B) Distribution of mutations along the NRF2 polypeptide. (C) PyMOL
representation of the interaction between the NRF2/MAFF heterodimer and the ARE element. Blue, NRF2; pink, MAFF. The red arrows indicate
possible mechanisms of inhibition of NRF2 by small molecules that could target the bZip domains of interaction between NRF2 and MAF proteins (PPI
inhibitors) or the interface of interaction of the NRF2-MAF heterodimer with the ARE [DNA–protein interaction (DPI)].
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and to activation of AMPK. The process is regulated by
caveolin-1, which binds directly to both NRF2 and
KEAP1, and impedes on NRF2 activation and hence
on the glycolytic shift. This is apparently one explana-
tion why glycolytic tumors, which are generally more
aggressive, have a caveolin-1low/Mn-superoxide dismu-
tasehigh phenotype (Hart et al., 2016). NRF2 can also
drive glucose and glutamine toward anabolic pathways
required for tumor cell proliferation (Mitsuishi et al.,
2012). In the presence of active PI3K–AKT signaling
and loss of KEAP1 activity, NRF2 was shown to induce
the shift of glucose metabolism from glycolysis toward
anabolic pathways (purine synthesis) in cancer
(Mitsuishi et al., 2012; Xu et al., 2016a). This is under-
lined byNRF2-mediated transcription of genes involved
in the pentose phosphate pathway and generation of
NADPH (glucose 6 phosphate dehydrogenase; phospho-
gluconate dehydrogenase, malic enzyme 1, isocitrate
dehydrogenase 1, transketolase, and transaldolase),
along with genes involved in purine nucleotide synthe-
sis (phosphoribosyl pyrophosphate amidotransferase,
methylenetetrahydrofolate dehydrogenase 2).
The fact that activation of NRF2 confers a growth
advantage to cancer cells might argue that its pharma-
cologic activation in chronic diseases presented in this
work might imply a high risk of developing cancer.
However, it must be considered that the oncogenic
activity of NRF2 requires mutations in its gene or in
KEAP1, which results in very high and persistent
induction of NRF2 signaling. This is not the case in
pharmacological therapy, in which it is possible to
modulate drug dosing and NRF2 activity. Moreover,
empirical evidence indicates that subjects enrolled in
clinical trials with NRF2 activators do not exhibit
increased cancer risk. This is best exemplified in the
case of patients with MS, who have been taking the
NRF2 activator dimethyl fumarate for several years
since it was approved by the regulatory agencies in
2013. Conversely, the use of NRF2 inhibitors in cancer
patients might lead to manifestation of the pathophe-
notypes described in the NRF2 diseasome. This is a
possibility that will need further investigation when
NRF2 inhibitors reach the clinic.
V. Nuclear Factor (Erythroid-Derived 2)–
Like 2 Drugome
This section attempts to develop a NRF2 drugome
that might be useful for future clinical directions to
target therapeutically NRF2 centered on the pathophe-
notypes of the NRF2 diseasome. As stated in Fig. 2B,
the pharmacological activation of NRF2 is being pur-
sued for increasing its stability by targeting KEAP1.
These strategies are based on the discovery of either
electrophile compounds that alter the KEAP1 structure
or small molecules that prevent the docking of NRF2 to
KEAP1. Although not yet demonstrated empirically,
the GSK-3 inhibitors should prevent the recognition of
NRF2 by b-TrCP and some compounds could be discov-
ered to prevent binding of NRF2 to b-TrCP. The
inhibition of NRF2 is being analyzed with compounds
that target the bZip dimerization domain to prevent
formation of the active NRF2/MAF heterodimer. By
comparison with other transcription factors, it might be
possible to find small molecules that impede binding
of the NRF2/MAF heterodimer to the ARE (Fig. 9C).
This section summarizes the most important findings
from a translational point of view in both de novo drug
discovery and repurposing.
A. Electrophilic Nuclear Factor (Erythroid-Derived 2)–
Like 2 Inducers
Themajority of known physiologic or pharmacological
NRF2 inducers are electrophilic molecules that cova-
lently modify, by oxidation or alkylation, cysteine
residues present in the thiol-rich KEAP1 protein (Hur
and Gray, 2011; Satoh et al., 2013). KEAP1 is one of the
best-suited proteins to act as electrophilic or redox
sensor, as it contains 27 cysteine residues in humans
and functions as an electrophile trap. The cysteines
C151, C273, and C288 of KEAP1 appear to be the most
prone to electrophile reaction (Fig. 2B), although there
are some specificities (Yamamoto et al., 2008; Saito
et al., 2015). Electrophile adducts inhibit KEAP1 in two
different ways. One is induction of a conformational
change in KEAP1 that will result in loss of its binding
capacity to NRF2. The other is the blockade of the
interaction between KEAP1 and CUL3/RBX1, resulting
in sequestration of KEAP1 with NRF2 and further
stabilization of newly synthetized NRF2 (Rachakonda
et al., 2008; Baird and Dinkova-Kostova, 2013; Cleasby
et al., 2014; Saito et al., 2015).
At least 30 recent patents for NRF2 modulators are
indexed in the World International Property Organiza-
tion. These patents are protecting chalcone derivatives,
novel amide triterpenoid derivatives, deuterium-
substituted fumarate derivatives, 3-alkylamino-1H-
indolyl acrylate derivatives, withanolide, a benzyl
derivative containing an activated vinyl group, androgra-
pholide or [S]+apomorphine, and sesquiterpene lactone
derivative (Sun et al., 2017). Although most of these
compounds proved to be useful to some degree from a
preclinical proof-of-concept perspective, their clinical
value is to date generally very limited. Only a few of
them have entered clinical trials, and regulatory bodies,
such as Food and Drug Administration or European
Medicines Agency, have approved even fewer. We in
this study discuss the most developed NRF2 activators
along the translational pipeline.
Fumaric acid esters are the most prominent example
of a KEAP1 modifier, and dimethyl fumarate (DMF) is
to date the only Food and Drug Administration– and
European Medicines Agency–approved drug registered
as NRF2 activator. The monoester form of DMF,
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monomethyl fumarate (MMF), was described as its
active metabolite. DMF and MMF are Michael accep-
tors that directly react with cysteine residues present in
KEAP1 (Lin et al., 2011).
DMF and other fumaric acid esters have been used for
treating psoriasis for over 50 years, starting at a time
when the function of NRF2 was still unknown. This
compoundwas licensed in Europe under the commercial
name of Fumaderm. Clinical trials showed a decrease in
the psoriasis area and severity index to 50%–80% after
12–16 weeks of DMF therapy (Altmeyer et al., 1994;
Mrowietz et al., 1998). More recently, DMF has demon-
strated its efficacy in the treatment of adults with
moderate to severe chronic plaque psoriasis in a phase
III trial (BRIDGE) (Mrowietz et al., 2017). The mecha-
nism of action underlying fumarates in remission of
psoriatic lesions includes the decrease in the number of
peripheral T cells along with a shift from a Th1 toward a
Th2 immune response (Ghoreschi et al., 2011; Tahvili
et al., 2015). In another autoimmune disease, SLE,
fumaric acid esters have been used as systemic combi-
nation therapy in the treatment of severe, extensive,
and refractory cutaneous manifestations (Saracino and
Orteu, 2017).
DMF was approved in 2013 for the treatment of MS
under the commercial name Tecfidera (Xu et al., 2015).
The use of DMF in MS patients was propelled by
positive results obtained in the MS mouse model of
EAE. Significant therapeutic effects on the disease
course and histology were associated with a markedly
reduced macrophage-mediated inflammation in the
spinal cord. Multiplex cytokine analysis in blood evi-
denced an increase of the anti-inflammatory cytokine
IL-10 in DMF-treated animals (Schilling et al., 2006).
Moreover, DMF also improved preservation of myelin,
axons, and neurons inwild-type, but not inNrf22/2mice
(Ellrichmann et al., 2011). In humans, DMF demon-
strated a significant reduction of lesions and annualized
relapse rate in MS (Schimrigk et al., 2006). Two phase
III clinical trials, DEFINE and CONFIRM, substanti-
ated these results (Fox et al., 2012; Gold et al., 2012).
Therefore, DMF is currently used as the first line of
treatment of relapsing-remitting MS that cannot be
treated by traditional therapies. New formulations of
DMF are being tested and patented to improve drug
bioavailability and efficacy (Sun et al., 2017). For
instance, MMF has been used to develop a second
generation of NRF2 inducers as prodrugs (Zeidan
et al., 2014). The lead compound ALKS-8700, a 2-(2,5-
dioxo-1-pyrrolidinyl)ethyl ester derivative of MMF, is
rapidly converted into MMF in the body, hence in-
creasing its bioavailability and reducing gastrointesti-
nal side effects. ALKS-8700 is currently under phase III
clinical trial (EVOLVE MS).
DMF and MMF modulate the immune response. For
example, they inhibit the maturation of DCs by re-
ducing the release of inflammatory cytokines and hence
the ability of DCs to process antigens. Moreover, DMF
and MMF activate natural killer cells to lyse DCs and
enhance apoptosis of both DCs and T cells (Ghoreschi
et al., 2011; Al-Jaderi and Maghazachi, 2015). As such,
DMF and MMF impede T cell–mediated autoreactivity.
Some studies indicate that DMF also induces type II
DCs by triggering GSH depletion, which results in
enhanced HO-1 activity and suppression of STAT1
phosphorylation. These classic type II DCs suppress
Th1- and Th17-mediated responses in favor of Th2 ones.
Furthermore, the increased production of IL-10 by DCs
favors the differentiation of CD4+ T cells toward a
suppressive Treg phenotype (Ockenfels et al., 1998;
Ghoreschi et al., 2011). DMF also inhibits the nuclear
translocation of NF-kB (Peng et al., 2012) and conse-
quently the production of inflammatorymediators, such
as TNF-a, IL-1b, IL-6, chemokines, adhesionmolecules,
and nitric oxide in microglia and astrocytes (Brennan
et al., 2017), as well as in peripheral blood mononuclear
cells (Eminel et al., 2017). In addition, DMF exerts
antiangiogenic effects that are dependent on the down-
regulation of vascular endothelial growth factor
receptor-2 expression in endothelial cells (Meissner
et al., 2011). Recent findings indicated that DMF
reduced the number of CD4+, CD8+, Th1, and Th17
cells, whereas the CD4+/CD8+ ratio and the Th2 subset
were increased in the blood of these patients. Interest-
ingly, the inhibitory effects of DMF/MMF on T cell
activation were confined mainly to memory T cells (Wu
et al., 2017). These immunomodulatory activities of
DMF or MMF are important for the protection of
oligodendrocytes against ROS-induced cytotoxicity
(Scannevin et al., 2012).
Additional mechanisms might explain the inhibition
of NF-kB independently of NRF2 activation. Thus, DMF
may interact with cysteine residues in several proteins
that regulate NF-kB signaling (Blewett et al., 2016). In
addition, DMF inhibits ubiquitin-conjugating enzymes
and thus prevents the degradation of the IkB repressor
of NF-kB in response to IL-1b or Toll-like receptor
agonists (McGuire et al., 2016). Moreover, DMF binds
directly to specific cysteine residues in protein kinase
C-u, a key kinase involved in signaling by the T cell
receptor (Blewett et al., 2016). In addition, MMF and
DMF activate the hydroxycarboxylic acid receptor-2,
resulting in inhibition of NF-kB and downregulation of
proinflammatory cytokines and adhesion molecules
(Chen et al., 2014; Gillard et al., 2015) and leading to
decreased neutrophil infiltration (Chen et al., 2014).
Although these NRF2-independent effects would
be relevant in the acute inflammatory phase of EAE,
the neuroprotective efficacy of DMF during chronic
autoimmune demyelination depends on NRF2 activa-
tion (Linker et al., 2011). The clinical benefit of
DMF treatment in both Nrf22/2 and wild-type mice
was associated with a reduction of inflammatory
Th1 and Th17 cells, as well as with induction of
366 Cuadrado et al.
anti-inflammatory M2 monocytes. At the same time,
decreased expression of CD80 and CD86 costimulatory
molecules was observed in wild-type, but not inNrf22/2
mice, indicating that at least these effects were NRF2-
dependent (Schulze-Topphoff et al., 2016).
The success of DMF for the treatment of autoimmune
diseases indicates that other diseases that share com-
mon pathomechanisms underlined by chronic, low-
grade inflammation and pathologic ROS formation
might benefit from the repositioning of this drug. In a
mouse model of Huntington’s disease, the survival rate,
muscle function, and body weight were preserved with
DMF treatment, and this was associated with an
increased number of intact neurons (Ellrichmann
et al., 2011). Also, in a recent preclinical study of PD,
using the a-synucleinopathymodel of this disease, DMF
was neuroprotective in wild-type, but not in Nrf22/2
mice due to impaired autophagy induction (Lastres-
Becker et al., 2016).
DMF was shown to prevent endothelial dysfunction
and cardiovascular pathologic ROS formation and in-
flammation in diabetic mice (Sharma et al., 2017), and
decreased atherosclerosis, kidney dysfunction, and
other diabetic complications were reported in apolipo-
protein E–deficient mice after streptozotocin injection
(Tan et al., 2014). Additionally, several studies in-
dicated that DMF might exert antitumor activity by
inhibiting the NF-kB pathway, hence adding therapeu-
tic value in the treatment of aggressive cancers
(Kastrati et al., 2016). DMF is a relevant example of
the drug-repurposing concept within the network phar-
macology approach.
Synthetic triterpenoids are derivatives of 2-cyano-
3,12-dioxo-oleana-1,9(11)-dien-28-oate (CDDO; bardox-
olone, RTA401) that resemble the natural product
oleanolic acid. They exhibit Michael acceptor activity
through its a-b unsaturated scaffold and represent the
most potent inducers of NRF2 (Sun et al., 2017). They
interact with C151 of KEAP1 and impede its interaction
with CUL3, hence leading to NRF2 activation (Cleasby
et al., 2014). Proof-of-principle studies strongly support
the use of synthetic triterpenoids for degenerative
diseases and are being the focus of intensive research
as antioxidant modulators of inflammation by Reata/
Abbott. For instance, CDDO-imidazole (CDDO-Im
RTA403) induced in peritoneal neutrophils of wild-
type but not Nrf22/2 mice the expression of various
antioxidant genes (Hmox1, Gclc, Gclm, and Nqo1) and
attenuated LPS-induced ROS generation and produc-
tion of proinflammatory cytokines, consequently de-
creasing mortality (Thimmulappa et al., 2006b).
CDDO-ethyl amide (RTA405) and CDDO-CDDO-
trifluoethyl amide (RTA 404) had significant effects
across all endpoints measured in a toxin-induced PD
model (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
(Kaidery et al., 2013). In the EAE model of MS, CDDO-
CDDO-trifluoethyl amide suppressed inflammation,
pathologic ROS formation, and myelin degeneration
(Pareek et al., 2011).
CDDO-methyl ester (CDDO-Me, RTA 402) was the
first CDDO that reached in clinical trials for the
treatment of diabetic nephropathy (Pergola et al.,
2011). Although the results of the phase II were very
encouraging, CDDO-Me was later withdrawn at phase
III (BEACON trial) due to cardiovascular safety issues
(Zhang, 2013) that were not related to NRF2 but most
likely to an off-target alteration of endothelin signaling
(de Zeeuw et al., 2013; Chin et al., 2014). Currently,
CDDO-Me is under clinical study as potential treatment
of Alport syndrome and pulmonary hypertension
(Table 2). In an effort to improve its safety profile,
further studies have led to the development of CDDO-
difluoropropionamide (RTA-408, omaveloxone), which
is currently in phase II trial for the treatment of
Friedreich’s ataxia, ocular inflammation, and pain after
ocular surgery.
Oltipraz is an organosulfur compound that is used as
an antischistosomal agent and is currently in phase III
trial for the treatment of nonalcoholic steatohepatitis.
Advanced clinical trials for the treatment of Hunting-
ton’s disease are under development with minocycline,
an antibiotic that has demonstrated neuroprotective
properties due to NRF2 activation (Kuang et al., 2009).
Another NRF2 inducer in phase I clinical study for the
treatment of acute kidney disease is CXA-10, a nitro
fatty acid with anti-inflammatory properties through
the activation of NRF2 (Batthyany and Lopez, 2015).
Many other NRF2 inducers with the same mechanism
of action have been described in the last years (Buendia
et al., 2015a,b, 2016), and some are in preclinical
studies, such as the compound VEDA-1209, a chalcone
derivative with a good anti-inflammatory profile for the
treatment of ulcerative colitis.
SFN is an isothiocyanate produced from enzymatic
cleavage of the organosulfur compound glucoraphanin,
which is present in sprouts of broccoli, cabbage, and
other Brassicacea plants. The catalytic reaction is
driven by the enzymemyrosinase that is found in plants
and microbiota of the GI tract (Kensler et al., 2013).
More recently, SFN has been obtained by chemical
synthesis (Kim et al., 2015). Translation of SFN to the
clinic has been achieved by administration of SFN-
containing broccoli sprout powder to patients with
T2DM (Bahadoran et al., 2012). Broccoli powder de-
creased plasma malondialdehyde and oxidized low-
density lipoprotein (LDL) and increased the total
antioxidant capacity. Cardiovascular risk factors such
as serum triglycerides, oxidized LDL/LDL ratio, and
atherogenic index of plasma (log of triglycerides/high-
density lipoprotein ratio) were also reduced. Further-
more, proinflammatory markers such as C-reactive
protein and IL-6 were decreased. In a more recent
study, SFN administered as concentrated broccoli
sprout extract suppressed glucose production from
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TABLE 2
Selected NRF2 inducers acting as electrophilic modifiers of KEAP1
The reference corresponds to the code in ClinicalTrials.gov.
Compound Disease Clinical Trial Reference
Multiple sclerosis Approved
Psoriasis Approved
Rheumatoid arthritis Phase II NCT00810836
Adult brain glioblastoma Phase I NCT02337426
Cutaneous T cell lymphoma Phase II NCT02546440
Obstructive sleep apnea Phase II NCT02438137
Chronic lymphocytic leukemia small lymphocytic lymphoma Phase I NCT02784834
Multiple sclerosis Phase III NCT02634307
Diabetic nephropathy Phase II NCT00811889
Chronic kidney disease, T2DM, diabetic nephropathy Phase III NCT01351675
Liver disease Phase I/II NCT00550849
Hepatic impairment Phase I NCT01563562
Advanced solid tumors
Lymphoid malignancies
Phase I NCT00529438
NCT00508807
Alport syndrome PhaseII/III NCT03019185
Pulmonary hypertension Phase III NCT03068130
Pulmonary arterial hypertension Phase III NCT02657356
Renal insufficiency, T2DM Phase II NCT01053936
Mitochondrial myopathy Phase II NCT02255422
Friedreich’s ataxia Phase II NCT02255435
Inflammation and pain following ocular surgery Phase II NCT02065375
Corneal endothelial cell loss, ocular pain and inflammation,
cataract surgery
Phase II NCT02128113
Melanoma Phase I/II NCT02259231
Breast cancer Phase II NCT02142959
Non-small cell lung cancer, melanoma Phase I NCT02029729
Acute kidney injury Phase I NCT02248051
HD Phase II/III NCT00277355
Intracerebral hemorrhage Phase I/II NCT01805895
Retinitis pigmentosa Phase I/II NCT02140164
Intracerebral hemorrhage Phase I/II NCT03040128
NASH Phase III NCT02068339
Schistosomiasis Approved
Lung cancer Phase I NCT00006457
(continued )
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TABLE 2—Continued
Compound Disease Clinical Trial Reference
Ulcerative colitis Preclinical PK ——
Cystic fibrosis Phase II NCT01315665
Schizophrenia Phase II/III NCT02880462
Phase II NCT02810964
Phase II NCT01716858
COPD Phase II NCT01335971
Atopic asthmatics Phase I NCT01845493
Autism Phase II NCT01474993
Phase II NCT02909959
Phase II NCT02677051
Phase II NCT02654743
Phase I/II NCT02561481
Healthy Phase I NCT01008826
Phase I NCT02023931
Melanoma Phase I NCT01568996
Asthma Phase I NCT01845493
Phase I/II NCT01183923
Prostate cancer Phase II NCT01228084
Breast cancer Phase II NCT00843167
Lung cancer Phase II NCT03232138
Environmental carcinogenesis Phase II NCT01437501
Alcohol sensitivity Phase II NCT01845220
Aging Phase II NCT03126539
Allergic rhinitis Phase II NCT02885025
Helicobacter pylori infection Phase IV NCT03220542
T2DM Phase II NCT02801448
Head and neck squamous cell carcinoma, head and neck
cancer, tobacco-related carcinoma
Phase I NCT03182959
Subarachnoid hemorrhage Phase II NCT02614742
Breast neoplasm Phase I/II NCT02970682
Prostate cancer Phase I NCT02055716
NCT01948362
Brain ischemia Preclinical PK —
Alzheimer disease Phase II NCT02711683
Acute ischemic stroke Phase I/II NCT02149875
Vascular cognitive impairment Phase II/III NCT02993367
Cerebrovascular occlusion, collateral blood circulation, anterior
cerebral circulation infarction
Phase IV NCT02594995
(continued )
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hepatocytes by nuclear translocation of NRF2 and
decreased expression of key enzymes involved in gluco-
neogenesis. Moreover, SFN reduced fasting blood glu-
cose and glycated hemoglobin in obese patients with
T2DM (Axelsson et al., 2017). SFN-induced activation of
NRF2 protected renal cells against lupus nephritis by
reducing the ROS burden and by inhibiting the NF-kB
and TGF-b1 signaling pathways (Jiang et al., 2014a).
In regard to neurodegenerative diseases, it has been
shown that SFN crosses the blood brain barrier and
provides sufficient cerebral bioavailability to activate
the NRF2 signature and to reduce LPS-elicited neuro-
inflammation, as reflected in the reduction of proin-
flammatory markers (inducible nitric oxide synthase,
IL-6, TNF-a) and microgliosis in the hippocampus
(Innamorato et al., 2008). SFN also safeguarded dopa-
minergic neurons against the parkinsonian toxin
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and at-
tenuated astrogliosis and microgliosis (Jazwa et al.,
2011). In line with these findings, SFN reduced the
levels of phosphorylated tau and increased Beclin-1 and
LC3-II, suggesting that NRF2 activation might facili-
tate degradation of this toxic protein through auto-
phagy in the brain (Jo et al., 2014). SFN-treated rats
subjected to spinal cord injury had significantly
decreased levels of inflammatory cytokines, reduced
contusion volume, and improved coordination (Wang
et al., 2012). This drug also ameliorated EAE by
preserving the blood-brain barrier and by reducing
pathologic ROS formation and the number of inflam-
matory cells (Li et al., 2013). SFN has been used to date
in at least 32 clinical studies addressing chronic dis-
eases such as cancer, asthma, chronic kidney disease,
T2DM, cystic fibrosis, autism, and schizophrenia
(Duran et al., 2016; Houghton et al., 2016) (Table 2).
Altogether, these observations paved the way for the
development of other SFN-derived compounds exhibit-
ing an improved pharmacokinetic profile. SFN is an oily
substance with low stability in hydrophilic media. Its
physicochemical profile prompted Evgen Pharma
(Wilmslow, Cheshire, England) to develop a cyclodex-
trin complex formulation, Sulforadex, which is under
phase II clinical trial for the treatment of subarachnoid
hemorrhage. SFN was also hybridized with melatonin
to generate the ITH12674, a compound that was designed
to have a dual drug–prodrug mechanism of action for
treatment of brain ischemia (Egea et al., 2015).
Curcumin is the main curcuminoid found in turmeric
and has been used for the treatment of obesity, meta-
bolic syndrome, and prediabetes. A nontargeted
TABLE 2—Continued
Compound Disease Clinical Trial Reference
Cholestasis Phase II/III NCT00846963
HD Phase I NCT00514774
Barrett esophagus, low-grade dysplasia Phase II NCT01097304
Chronic hepatitis C Phase III NCT00200343
T2DM Phase II NCT02033876
T2DM Phase I NCT01677611
Colon cancer Phase I NCT00256334
COPD Phase III NCT02245932
Friedreich ataxia Phase I/II NCT01339884
NASH Phase II/III NCT02030977
Non-ischemic cardiomyopathy Phase III NCT01914081
Endometriosis Phase IV NCT02475564
Chronic renal insufficiency Phase III NCT02433925
Metabolic syndrome X Phase II NCT02114892
Chronic subclinic inflammation Phase III NCT01492114
AD Phase II NCT01504854
Phase III NCT00743743
Colorectal cancer Phase I NCT00433576
HD Phase III NCT02336633
T2DM, cardiovascular risk Phase IV NCT01052025
Schizophrenia, cognition, psychosis Phase I/II NCT02104752
Acute kidney injury, abdominal aortic aneurysm Phase II/III NCT01225094
Chronic kidney diseases, T2DM Phase II/III NCT03262363
AD Phase I/II NCT00164749
Neoplasms Phase II NCT02944578
Crohn’s disease Phase III NCT02255370
Chronic schizophrenia Phase IV NCT02298985
Mild cognitive impairment Phase II NCT01811381
Prostate cancer Phase III NCT02064673
Major depression Phase IV NCT01750359
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metabolomics study to investigate the effects of curcu-
min on rat liver was conducted by means of gas
chromatography with electron impact mass spectrome-
try. The intermittent intake of curcumin upregulated
NRF2 and displayed antioxidant and anti-inflammatory
roles in the protection against liver damage (Qiu et al.,
2016). Oral consumption of curcumin is effective in
lowering serum triglycerides, IL-1b, IL-4, and vascular
endothelial growth factor, and in increasing adiponectin
levels in blood. In T2DM patients, curcumin decreases
the levels of fasting blood glucose, glycated hemoglobin,
serum free fatty acids, triglycerides, and uric acid, and
increases the levels of lipoprotein lipase (Na et al., 2013;
Chuengsamarn et al., 2014).
Resveratrol is a polyphenol that protects plants
against fungal infection and is found in the skin of
grapes, red wine, berries, and many other plants.
Resveratrol exerts antioxidant properties through acti-
vation of NRF2 signaling by downregulating KEAP1
expression and by activating the protein deacetylase
sirtuin-1 (Ungvari et al., 2010). In healthy subjects, the
dietary administration of resveratrol prevented the
elevation in plasma of cholesterol, endotoxins, pro-
oxidants, and inflammatorymarkers (p47phox, KEAP1,
IL-1b, and TNF-a). These events correlated with the
elevation of NRF2 activity as determined by enhanced
expression of its targets NQO1 and glutathione
S-transferase (Ghanim et al., 2011). In T2DM patients,
insulin sensitivity was improved after 4 weeks of
treatment, as determined by enhanced insulin signaling
via AKT, decreased pathologic ROS formation, and
reduced levels of glycated hemoglobin (Brasnyo et al.,
2011; Bhatt et al., 2012). Overall, resveratrol was
reported to prevent major cardiovascular, inflamma-
tory, oxidative, and metabolic complications in hyper-
tension, hypercholesterolemia, atherosclerosis, ischemic
heart disease, diabetes, and metabolic syndrome in
animal models and patients (Xia et al., 2017).
A problem that is frequently overlooked is the lack of
selectivity of electrophilic KEAP1 inhibitors. Electro-
philes react with different nucleophiles present in the
cell, thus exhibiting off-target and nondesired side
effects. For instance, CDDO-Im can interact with more
than 500 different targets (Yore et al., 2011). In general,
several protein phosphatases contain redox-sensitive
cysteines in their catalytic center, and some KEAP1
inhibitors may modify and inactivate these phospha-
tases, hence disturbing signaling networks. One of
these phosphatases is PTEN (Lee et al., 2002;
Kitagishi and Matsuda, 2013; Han et al., 2015). The
catalytic C124 residue of PTEN can bemodified through
adduct formation with strong electrophiles such as
CDDO-Im (Pitha-Rowe et al., 2009) and tert-
butylhydroquinone (Rojo et al., 2014b). Then, the in-
creased activation of the PI3K/AKT pathway involves
inhibition of GSK-3 and subsequent stabilization of
NRF2 (Fig. 2C) (Rada et al., 2011, 2012). Moreover,
KEAP1 interacts with other proteins that also contain
the high-affinity bindingmotif ETGE (Hast et al., 2013),
such as Bcl-2 and IKKb (Kim et al., 2010a; Cazanave
et al., 2014). Therefore, some results obtained from
KEAP1-deficient cells may not necessarily be related to
NRF2 activation.
B. Protein–Protein Interaction Inhibitors for Nuclear
Factor (Erythroid-Derived 2)–Like 2 Activation
To overcome the pitfall of selectivity, a new class of
NRF2 inducers that prevent the docking of NRF2 to
KEAP1 has emerged (Richardson et al., 2015). The use
of PPI inhibitors has been achieved by the prior
elucidation of the X-ray crystal structure of KEAP1
(Padmanabhan et al., 2006) bound to a peptide contain-
ing the high-affinity binding ETGE motif of NRF2 (Lo
et al., 2006). KEAP1 contains a six-bladed b-propeller
with specific hydrophobic and hydrophilic residues that
participate in the docking of theETGEmotif that adopts
a b-hairpin structure. Docking is mainly favored by
electrostatic interactions between several arginines of
KEAP1 and the two glutamates in the ETGE motif (Lo
et al., 2006; Padmanabhan et al., 2006). The docking to
KEAP1 of the low-affinity DLG motif of NRF2 has also
been characterized (Tong et al., 2007). Based on these
interactions, peptidomimetic compounds were the first
example of PPI inhibitors with significantly improved
selectivity over electrophiles (Hu et al., 2013; Marcotte
et al., 2013; Winkel et al., 2015). These inhibitors show
weak activity in cells, and a new provocative strategy
has now been reported based on the use of cyclic
peptides. One of these peptides exhibited high-binding
affinity for KEAP1 and activation of NRF2 and elicited
anti-inflammatory effects in mouse macrophages (Lu
et al., 2018).
The discovery of new peptides and small-molecule
inhibitors of the KEAP1/NRF2 interaction has been
reviewed recently (Abed et al., 2015; Jiang et al., 2016).
Briefly, a series of truncated NRF2 peptides was
initially evaluated as direct inhibitors of PPI using
surface plasmon resonance and fluorescence polariza-
tion assays (Hu et al., 2013). The minimal peptide
sequence with inhibitory capacity was the 9-mer se-
quence of LDE-ETGE-FL (Chen et al., 2011; Inoyama
et al., 2012). In parallel, Wells and collaborators
(Hancock et al., 2013) searched for new putative peptide
ligands using a phage display library combined with
high-throughput fluorescence polarization assay. They
found that hybrid peptides based upon the ETGE motif
of NRF2 and SQSTM1 have superior binding activity to
KEAP1 compared with either native peptide alone. To
facilitate cellular uptake, a peptide was designed with
the ETGEmotif fused to the cell transduction domain of
the HIV-Tat protein and the cleavage sequence of
calpain (DEETGE-Cal-Tat). This peptide showed neu-
roprotective and cognitive-preserving effects in amouse
model of cerebral ischemia (Tu et al., 2015).
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TABLE 3
Selected NRF2 inducers acting as NRF2–KEAP1 protein–protein interaction inhibitors
Compound Patent Title Applicant
WO2017060855 Arylcyclohexyl pyrazoles as NRF2
regulators
GlaxoSmithKline Astex
Therapeutics
WO2016/202253 NRF2 regulators GlaxoSmithKline Astex
Therapeutics, GlaxoSmithKline
(China), R&D
WO2014/197818 Small-molecule activators of NRF2
pathway
General Hospital, Regents of the
University of California
WO2013/067036 Direct inhibitors of KEAP1–NRF2
interaction as antioxidant
inflammation modulators
Rutgers, The State University of
New Jersey, Broad Institute
WO2011/156889 Novel modulators of NRF2 and
uses thereof
TRT Pharma Gerald Batist, Jian
Hui Wu
JP2011/0167537 KEAP1 protein-binding compound,
crystal of complex between the
same and KEAP1 protein, and
method for producing the same
Toray Industries
(continued )
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Five families of PPI inhibitors have been described:
tetrahydroisoquinoline (Jnoff et al., 2014; Richardson
et al., 2015), thiopyrimidine (Marcotte et al., 2013),
naphthalene (Jiang et al., 2014b), carbazone (Ranjan
et al., 2014), and urea derivatives (Sato et al., 2013).
Table 3 compiles recent patents addressing these
small molecules. Although these compounds are very
promising, it is still needed to demonstrate that they are
selective for the KEAP1/NRF2 interaction, because
KEAP1 also targets at least Bcl2 and IKK (Kim et al.,
2010a; Hast et al., 2013; Cazanave et al., 2014).
From the large number of compounds indexed in the
available libraries, the compounds LH601, benzenesulfonyl-
pyrimidone 2, N-phenyl-benzenesulfonamide, and a series
TABLE 3—Continued
Compound Patent Title Applicant
WO2017124835 1-sulfonamido-4-aryloxy
compound, and preparation
method and medicinal
application thereof
China Pharmaceutical University
WO2015/092713 NRF2 regulators GlaxoSmithKline Astex
Therapeutics Limited
WO2011156889A1 Novel regulators of NRF2 and uses
thereof
TRT Pharma Gerald Batist, Jian
Hui Wu
WO2016/202253 NRF2 regulators GlaxoSmithKline Astex
Therapeutics, GlaxoSmithKline
(China), R&D CO., LTD
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of 1,4-diphenyl-1,2,3-triazoles might be very well-suited
candidates to inhibit the PPI with KEAP1 (Hu et al.,
2013; Jnoff et al., 2014; Bertrand et al., 2015; Wen
et al., 2015; Nasiri et al., 2016). These studies de-
scribed in detail the atomic interaction with KEAP1,
the affinity, and the thermodynamics parameters of
binding. The therapeutic efficacy of these compounds
is to be analyzed in future work in which safety,
potency, and blood brain barrier permeability should
be addressed.
C. Drug Targets Other Than Kelch-Like
ECH-Associated Protein 1 for Nuclear Factor
(Erythroid-Derived 2)–Like 2 Activation
Protein kinase GSK-3 phosphorylates the two serine
residues in the DSGIS sequence of NRF2 to generate a
phosphorylation-dependent degradation motif or phos-
phodegron (Fig. 2). This phosphodegron is recognized by
the E3 ligase adapter b-TrCP, leading to ubiquitin-
dependent proteasomal degradation of NRF2. There-
fore, GSK-3 inhibitors should stopNRF2 degradation by
preventing the generation of this phosphodegron. GSK-3
is an important kinase in AD and other pathophenotypes.
It phosphorylates the cytoskeletal protein tau, facilitating
the formation of neurofibrillary tangles, which are path-
ologic intracellular aggregates that disturb axonal trans-
port and lead to neuronal death (Silva et al., 2014).
Therefore, it has been speculated that GSK-3 inhibition
might have the double benefit of preventing neurofibril-
lary tangle formation and NRF2 degradation. Unfortu-
nately, most pipelines for the development of GSK-3
inhibitors have been discontinued due to futility, although
in most cases there was not good evidence of target
modulation (Palomo and Martinez, 2017).
Conceptually, inhibitors of the b-TrCP-phosphoNRF2
interaction should also lead to NRF2 activation as they
should disrupt this branch ofNRF2 degradation (Fig. 2).
The molecular interactions between the b-propeller of
b-TrCP and a peptide containing the NRF2 phosphode-
gron have been resolved by NMR (Rada et al., 2012). As
it happens for KEAP1/EGTE, the most relevant amino
acids appear to be several arginine residues of b-TrCP
that interact with the two phosphoserines of the
DpSGIpS motif. However, the discovery of small mole-
cules that could inhibit the b-TrCP-phosphoNRF2 in-
teraction is still to come.
Additional strategies have been developed to inhibit
the NRF2 repressor BACH1, a bZip protein that makes
heterodimers with MAF proteins and blocks expression
of ARE genes. Efficient inhibition of BACH1 by the
HPP-4382 compound has been described in vitro
(Attucks et al., 2014), but, prior to a full clinical trial,
the safety and efficacy profile of HPP-4382 will have to
be demonstrated in vivo. Considering that other path-
ways may also influence NRF2 activity, it is reasonable
to speculate that a combinatorial approach will be the
best way to activate this transcription factor.
D. Nuclear Factor (Erythroid-Derived 2)–
Like 2 Inhibitors
NRF2 has a “dark side” related to its oncogenic
activity when constitutively and highly overexpressed.
Therefore, NRF2 inhibition has been proposed as a
mechanism to sensitize cancer cells to chemotherapeu-
tic drugs or radiotherapy (Milkovic et al., 2017). Two
strategies can be envisioned to inhibit NRF2 with small
molecules: PPI inhibitors that disrupt the bZip interac-
tion between NRF2 and MAFs, and DNA–protein in-
teraction inhibitors that block binding of NRF2-MAF to
the ARE (Fig. 9C). Both strategies are hampered by the
need by such drugs to overcome the large free energy of
association between protein–protein and, to a lesser
extent, protein–DNA interfaces. Nevertheless, such
drugs have been found for other bZip transcription
factors such as STAT3-STAT3, MYC-MAX, and JUN-
FOS (Yap et al., 2011), and new small molecules are
being described for NRF2-MAF. For instance, malabar-
icone-A is a pro-oxidant compound that overcomes
leukemia resistance by targeting NRF2 (Manna et al.,
2015). Ascorbic acid (vitamin C), a well-known ROS
scavenger, was found to sensitize imatinib-resistant
cancer cells by decreasing the levels of the NRF2/ARE
complex, reducing the expression of theGCLC gene and
dropping GSH levels (Tarumoto et al., 2004). All-trans-
retinoic acid is another example of NRF2 inhibitor that
significantly decreases NRF2 activation by potent elec-
trophilic NRF2 inducers in vitro and in vivo. It activates
the retinoic acid receptor a, which forms a complex with
NRF2, hence impeding the binding of the transcription
factor to ARE genes (Wang et al., 2007).
Natural products such as brusatol (Ren et al., 2011;
Olayanju et al., 2015), ochratoxin A (Tarumoto et al., 2004;
Limonciel andJennings, 2014), and trigonelline (Arlt et al.,
2013) have also been found to inhibit NRF2. However,
theirmechanism of action is not fully understood. In fact, a
significant issue related to currently available compounds
is the profound off-target effect that they might have. For
instance, promising results with brusatol were recently
discouraged by the finding that this drug exerts a general
and unspecific inhibition of protein synthesis, resulting in
the drop of NRF2 levels, but also of many other proteins
with rapid turnover (Harder et al., 2017). Similarly, the
antiprotozoal agent halofuginone, used in veterinary
practice, enhances the chemosensitivity of cancer cells by
suppressingNRF2accumulation, but this effect appears to
be indirect by inhibiting prolyl–transfer RNA synthesis
that is strongly required for ribosomal translation ofNRF2
as well as many other proline-containing proteins
(Tsuchida et al., 2017).
A novel approach to identify selective NRF2 inhibitors
has been reported recently by the use of quantitative high-
throughput screen of small-molecule inhibitors (Singh
et al., 2016). The authors identified a first-in class
compound, termed ML385, which most likely prevented
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the binding of NRF2 to other bZip coactivators. This
compound blocked NRF2 transcriptional activity and
sensitized KEAP1-deficient cells to carboplatin and other
chemotherapeutic drugs. Additional studies are needed to
confirm whether ML385 is selective for NRF2 or if it also
inhibits other bZip transcription factors.
In light of the highly favorable systemic effects of
NRF2 in various tumor pathophenotypes, a specific
targeting of NRF2with small-molecule inhibitors seems
to provide an excellent clinical approach. However, it is
necessary to determine whether cancer treatment with
NRF2 inhibitors increases the risk of other pathophe-
notypes of the NRF2 diseasome.
E. Repurposing Instead of De Novo Drug Discovery
and Development
As previously discussed, numerous compounds are
under development to provide a benefit for the patho-
phenotypes associated with the NRF2 diseasome. An
alternative approach is to give drugs that are already in
clinical use for a certain pathomechanism a new use for
the treatment of other pathomechanisms that are
connected to NRF2. This section provides the basis for
repositioning some commonly used drugs based on their
role in NRF2 regulation.
Metformin is the first-line monotherapy for the
T2DM. According to Fig. 6, it provides therapeutic
benefit to the NRF2 subcluster of pathophenotypes
related to glucose metabolism. In fact, SFN reduces
hepatic glucose production and improves glucose con-
trol in patients with T2DM (Axelsson et al., 2017).
Interestingly, some evidence suggests that metformin
may be effective in preventing other nonglycemic
pathophenotypes of the NRF2 diseasome, including
cardiovascular (Nesti and Natali, 2017), respiratory
(Sato et al., 2016), digestive (Bauer and Duca, 2016),
neurodegenerative (Markowicz-Piasecka et al., 2017),
autoimmune (Schuiveling et al., 2017), and neoplastic
(Heckman-Stoddard et al., 2017) disorders. The mech-
anism of action of metformin is not completely clear, but
it involves inhibition of mitochondrial complex I, thus
increasing the AMP/ATP ratio (El-Mir et al., 2000;
Owen et al., 2000) and leading to activation of the
energy sensor AMPK (Hardie, 2004; Rena et al., 2017).
Importantly, AMPK activates NRF2 (Wang et al.,
2017a; Zhao et al., 2017), and pharmacological targeting
of this axis attenuates inflammation after stroke (Wang
et al., 2017c) or endotoxin exposure (Ci et al., 2017; Lv
et al., 2017). Indeed, metformin activates NRF2 in an
AMPK-dependent manner, resulting in inhibition of
inflammatory responses in preclinical rodent models of
transient global cerebral ischemia (Ashabi et al., 2015;
Kaisar et al., 2017). Glucose metabolism and inflam-
mation may not be the only pathomechanisms affected
by metformin/NRF2. In fact, other salutary effects have
been described for redox (Kocer et al., 2014; Kelleni
et al., 2015) and protein homeostasis (Tsai et al., 2017).
Statins prevent and reduce cardiovascular patho-
phenotypes. In addition to a lipid-lowering effect,
statins appear to protect against pathomechanisms
associated with the NRF2 network such as inflamma-
tory (Pantan et al., 2016; Wu et al., 2016a; Hwang
et al., 2017) and pathologic ROS formation
(Abdanipour et al., 2014). They are competitive inhib-
itors of 3-hydroxy-3-methyl-glutaryl-CoA reductase,
which catalyzes the rate-limiting reaction in cholesterol
synthesis. Other pleiotropic effects include the upregu-
lation of transcription factor Krüppel-like factor 2,
which is induced early during progression of cirrhosis
and lessens the development of hepatic vascular dys-
function (Marrone et al., 2015). Recent evidence indi-
cates that at least some statins activate NRF2. In a
proteomic study conducted in isolated hepatocytes, high
concentrations of simvastatin activatedNRF2, probably
as a defensive mechanism (Cho et al., 2013). The
pretreatment of neural stem cells with lovastatin
activated the NRF2 pathway and elicited protection
against hydrogen peroxide–induced cell death
(Abdanipour et al., 2014). In liver cirrhosis, simvastatin
activates an axis formed by Krüppel-like factor 2 and
NRF2 to reduce the oxidative burden and inflammatory
response of stellate cells, improving liver fibrosis,
endothelial dysfunction, and portal hypertension. The
mechanism of activation of NRF2 by simvastatin is not
completely clear, but it appears to involve elements
found in the NRF2 interactome, such as mitogen-
activated protein kinase, PI3K/AKT pathways (Jang
et al., 2016), and GSK-3 (Lin et al., 2016).
Other cases for drug repurposing can be inferred from
the NRF2 interactome of Fig. 4, in particular with
signaling kinases. As indicated in Fig. 2C, GSK-3
phosphorylates the Neh6 domain of NRF2, leading to
the recognition by b-TrCP and further ubiquitin-
dependent proteasomal degradation. GSK-3 is active
in the absence of stimuli and inactive when signaling
cascades that activate AKT and other kinases lead to
phosphorylation of GSK-3 at its N-terminal pseudosub-
strate domain. It follows that medications known to
target signaling kinases may be used to upregulate
(GSK-3 inhibitors) or downregulate (PI3K/AKT inhibi-
tors) the NRF2 signature.
GSK-3 participates in at least some pathophenotypes
found in the NRF2 diseasome such as diabetes and
neurodegeneration (Beurel et al., 2015; Maqbool and
Hoda, 2017). A broad spectrum of GSK-3 inhibitors has
been discovered from natural and synthetic origins
(Khan et al., 2017), but probably the best evidence for
repurposing a GSK-3 inhibitor to increase NRF2 activ-
ity stems from the clinical use of lithium as mood
stabilizer (Chiu et al., 2013). Although bipolar disorder
and depression are not found at this time in the NRF2
diseasome, it is becoming evident that they exhibit
neuroinflammatory and degenerative pathophenotypes
that at least in mouse models imply deregulation of
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NRF2 (Martin-de-Saavedra et al., 2013; Freitas et al.,
2016; Yao et al., 2016).
The NRF2 interactome also provides a justification
for the inhibition of NRF2 by cancer drugs that block
signaling kinases, thus activating GSK-3. For example,
the epidermal growth factor receptor inhibitor erlotinib
leads to NRF2 inhibition, participating in tumor cell
sensation in nonsmall cell lung cancer (Xiaobo et al.,
2016). The kinase cascade inhibitor sorafenib, used in
therapy of hepatocellular carcinoma, also leads to in-
hibition of NRF2 and its downstream targets
metallothionein-1 (Houessinon et al., 2016) and meth-
ylenetetrahydrofolate dehydrogenase 1 (Lee et al.,
2017).
Finally, search for repurposing drugs that might
impinge on NRF2 regulation has been done to date in
two relevant studies. Using a fluorescence correlation
spectroscopy-based screening system, two of 1633 drugs
significantly increased NRF2 protein levels in HepG2
cells: chlorophyllin and bonaphton (Yoshizaki et al.,
2017). In another study, the connectivity map database
that comprises gene expression profiles for human cell
lines treated with 1309 agents (Lamb et al., 2006; Iorio
et al., 2010) was analyzed (Zhang et al., 2017) in search
for potential redox regulators through activation of
NRF2 (Xiong et al., 2014). This study found astemizole,
a potent antihistamine drug, used in allergic conditions,
as a novel NRF2 activator.
VI. Biomarkers as Nuclear Factor (Erythroid-
Derived 2)–Like 2 Signature and for Monitoring
Target Engagement
The evaluation of the redox status in patients or
population studies is hampered by the short half-life of
ROS, in the range of milliseconds or nanoseconds
(Ghezzi et al., 2017b). Therefore, biomarkers of patho-
logic ROS formation are based on measuring the traces
left by ROS, which are normally terminal oxidation
products of cellular molecules, many of them being
nonspecific (Frijhoff et al., 2015). On the contrary,
activation of NRF2 and subsequent expression of its
target genes is an indirect but reliable estimation of the
total exposure of the organism to pathologic ROS
formation. Because NRF2 activation is a well-
established cellular response to environmental stres-
sors, it has been considered as biomarker of exposure to
xenobiotics. In lung, a data mining of several transcrip-
tion studies followed by Ingenuity pathway analysis
reported that the NRF2 signature is upregulated in
healthy smokers, therefore suggesting that NRF2-
regulated antioxidant genes play a central role in
protection against toxic effects of tobacco smoke
(Comandini et al., 2010). Similarly, the levels of
NQO1, an enzyme regulated by NRF2, were 15-fold
higher in liver tissue obtained from acetaminophen-
overdosed patients (Aleksunes et al., 2006). The
association between disease and nutrition is frequently
based on unreliable self-reporting (Archer et al., 2015).
Measuring biomarkers of response to nutrients, sup-
posedly having beneficial effects by activating NRF2,
could provide a reliable method to validate nutritional
studies. However, this possibility is still unexplored.
The changes associated with NRF2 transcription
could be useful as biomarker for monitoring the efficacy
of drugs aimed at reducing pathologic ROS formation by
inhibitors of xanthine oxidase and NADPH oxidase.
Similarly, exposure to environmental chemicals could
be detected and monitored by defining a global protein
and gene expression profile (Ghezzi et al., 2017a). This
approach is similar to the use of phase I drug-
metabolizing enzymes, in which cytochrome P450,
which is induced by various xenobiotics through the
Ah receptor, can be used as indicator ofmarine pollution
(Cajaraville et al., 2000). Daily oral administration of
fumaric acid esters over 12 weeks was associated with
the increased expression of NRF2 target genes in the
skin of patients with psoriasis (Onderdijk et al., 2014).
Similarly, a fivefold increase in the mRNA level of
NQO1 has been reported in peripheral blood mono-
nuclear cells obtained from cancer patients that re-
ceived a daily dose of CDDO-Me for 3 weeks (Hong et al.,
2012).
The use of the transcriptional signature of NRF2 as a
biomarker requires a good knowledge of the mecha-
nisms involved in activation of ARE genes, as most of
the NRF2 targets are regulated by additional transcrip-
tion factors. It is therefore important to analyze the
expression of several ARE genes. For instance, a study
using NRF2 as predictor for response to treatment in
lung squamous cell carcinoma has proposed the use of
28 genes to define a NRF2 activation profile (Cescon
et al., 2015).
VII. Conclusions
Systems medicine together with network pharmacol-
ogy highlights a cluster of chronic disease pathopheno-
types in which NRF2 plays a fundamental role. These
diseases share common mechanisms, including oxida-
tive, inflammatory, and metabolic alterations. The
NRF2 interactome, the NRF2 diseasome, and the
NRF2 drugome presented in this work are still in an
early stage of development, but they represent a first
attempt to structure NRF2 as a common therapeutic
and systems medicine approach. The forthcoming re-
finement of current databases and upcoming clinical
outcome data will further improve the accuracy of this
new approach to pharmacology and mechanism-based
drug repurposing. This paper provides a road map for a
comprehensive strategy for drug discovery to activate or
inhibit NRF2 and highlights the need of translational
efforts toward the development of de novo drugs or the
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repurposing of drugs that target NRF2 as a common
element in chronic diseases.
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